THE UK ONCOLOGY NURSING SOCIETY

England & Wales · Charity number 1136972

Details

Other names	UKONS
Status	Registered
Legal form	Charitable company
Company number	06996552
Registered	2010-07-20
Register	View on the Charity Commission register

Contact

Address	Office 605 Albert House 256-260 Old Street London EC1V 9DD
Phone	07974179262
Email	ukons@media1productions.co.uk
Website	http://www.ukons.org

Activities

Objects: THE OBJECTS OF THE CHARITY ARE, FOR THE PUBLIC BENEFIT:1.1 TO ADVANCE HEALTH AND TO RELIEVE THOSE IN NEED BY REASON OF ILL-HEALTH, INCLUDING WITHOUT LIMITATION PEOPLE AFFECTED BY CANCER; AND1.2 TO ADVANCE THE EDUCATION OF THE PUBLIC IN THE SUBJECTS OF HEALTH, MEDICAL AND NURSING CARE, INCLUDING WITHOUT LIMITATION THE CAUSES, EFFECTS AND TREATMENTS OF CANCER.

Activities: UK Oncology Nursing Society supports training, education and general support to cancer nurses across the 4 nations of the UK.

Classification

- **How:** Acts As An Umbrella Or Resource Body
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

Downloaded from opencharities.uk/ew/1136972

Geography

- **Area of benefit:** UNDEFINED. IN PRACTICE, NATIONAL
- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£136,385	£131,357	-	-
2024-03-31	£224,352	£290,856	-	-
2023-03-31	£100,649	£149,089	-	-
2022-03-31	£111,210	£90,710	-	-
2021-03-31	£109,646	£80,587	-	-

Downloaded from opencharities.uk/ew/1136972

Trustees

Name	Role	Appointed
Dr Mary Anne Tanay	Chair	2018-11-17
Bethany Maynard		2024-12-04
Constance Elizabeth Rowell		2021-12-10
Dr Barry Gerard Quinn		2023-11-18
Dr Joanne Bird		2020-12-09
Dr Linda Sherwood		2023-11-18
Dr karen campbell		2018-11-17
Hilary Baker		2025-12-04
Jane Louise Ewang		2024-12-04
Lara Roskelly		2025-12-03
NAOMI RUTH CLATWORTHY		2021-12-10
Nicola Jones		2024-12-04
Rachel Bryce		2024-12-04
Ruth Louise Hammond		2021-12-10
Vicki Havercroft Dixon		2025-12-03

Downloaded from opencharities.uk/ew/1136972

THE UK ONCOLOGY NURSING SOCIETY

England & Wales - Charity number 1136972

Accounts

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Unaudited Financial Statements

Year Ended 31 March 2025

Company Registration Number 06996552
Charity Registration Number 1136972

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Financial Statements

Year Ended 31 March 2025

Contents **Page**

Trustees' Report	1
Independent Examiner’s Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The trustees have pleasure in presenting their report and the unaudited financial statements of the charitable company for the year ended 31 March 2025.

Status

The charitable company is limited by guarantee, having no share capital. Under the provisions of Section 60 of the Companies Act 2006, the company is entitled to omit the word "Limited" from its name. The governing document of the charitable company is its Memorandum and Articles of Association.

The charitable company is also known as UKONS.

Objects and Activities of the Charity

The objects of the charitable company are, for the public benefit:

1. To advance health and to relieve those in need by reason of ill-health, including without limitation people affected by cancer; and

2. To advance the education of the public in the subjects of health, medical and nursing care, including without limitation the causes, effects and treatments of cancer.

Aims of the charity

- To promote excellence in the nursing care and management of all those directly and indirectly affected by cancer.
- To encourage and facilitate the personal and professional development of nurses engaged in cancer care throughout the UK and overseas through education, research and policy.
- To share information about research, learning and development opportunities with UKONS members.
- To contribute to the development of cancer policy, clinical practice and service delivery nationally and internationally.
- To foster alliances and develop UK and international networking opportunities.

Activities and achievements aligned to the charity's aims for the year 2024/25

- Continuation of the Members Interest Groups: Personalised Cancer Care; Acute Oncology Services; Systemic Anti-cancer Treatments; Radiotherapy; Haemato-oncology; Lead Cancer Nurses; Research
- A further Members Interest Group- 'Young and Early Career Cancer Nurses' was added in 2021 and fully established as an interest group with annual webinar activity and a Facebook and social media presence.
- UKONS as part of the SACT interest group has implemented a practice educator forum.
- Continuation of our provision of the UKONS website (www.ukons.org), catering to the needs of members and the members interest groups.
- Continued publication of fortnightly editions of UKONS 'Breaking News' bulletin, supporting 'top stories' from practice, workforce surveys, academic and study day opportunities. This aids practice development and career progression. Breaking news is sent to all member via e-mail. Breaking news also includes cancer nurse job advertisements, which are offered free of charge.
- In 24/25 the collaboration for Breaking News continues to be delivered jointly between UKONS and Macmillan Cancer Support. This collaboration is underpinned by an MOU agreement and signed by both parties, renewed in 2024.
- As the main output from UKONS the in person annual conference continues to gain internet in both abstract submissions and attendance. Last year's themes was Working towards positive change in cancer care", which was held at the Manchester Conference Centre on November 14–15, 2024. This provided the opportunity for cancer nurses to present orally, and through posters on education,

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

innovation and research. The conference programme and abstracts were held in a handheld application for ease before and during the conference. Last year we aimed to increase the number of sessions where chose abstracts presented in breakout sessions and the plenary sessions.

SACT Members Interest Group:

- After the launch of the SACT passport in January 2024 , this mobile application is currently being implemented and embed into practice with a distribution across the four nations of the UK. The reach includes Southern Ireland. This mobile application is being embedded both in NHS trust and academic institutions. The collaboration continues with the competency passport application ' Compassly' and Tefogo Ltd.
- During 2024/25 UKONS continued to be a prominent member of the UK SACT Board (formally UK Chemotherapy Board) delivering guidelines across all four nations for the delivery of systemic anti-cancer therapies.
- The SACT MIG also delivered three webinars across the year.
- Noted a change in SACT link board
- Hypersensitivity Guidelines developed.

Acute Oncology Members Interest Group:

- Continued to approve translations of the UKONS Acute Oncology Triage Tool as well as working to formalise and deliver electronic versions of the tool.
- The eLearning course in partnership with E learning for Health NHS England. Is being requested for access internationally (Malta and Florida).
- UKONS launched with the UK Acute Oncology Society and Macmillan to standardise AO education, training and assessment and advanced work on multi-professional AO competency passports.
- The AOS MIG delivered one webinar with 400 delegates.
- Presented at AOS Ireland conference
- Presented at Oncology Forum Conference.

Personalised Cancer Care Members Interest Group:

- This Mig continues to evolve and define the focus
- Held one webinar 24/25
- Personalised Cancer Care book is in progress.

Radiotherapy Members Interest Group:

- Held a webinar and first breakout session at the annual conference.

Haematology Members Interest Group:

- Has delivered three webinars in collaboration with partners and charity organisations.
- Held first break out session at the annual conference.
- Has held a well-attended session at the British haematology Society conference in Glasgow.
- Continues to seek partnerships for education and research Grants.
- Online Survey for learning needs
- Involved in a systematic review for Seminar in Oncology Nursing

Research Members Interest Group:

- Research is now present in all Migs
- Research continues to review research and survey requests.

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

Education Competency and Capability:

- UKONS continued to be a central organisation in promoting the ACCEND (Aspirant Cancer Career and Education Development) programme. This career framework provides guidance and structure or all health care professionals wishing to develop a career in cancer care.
- Organised and presented education, training sessions and symposia at virtual and face-to-face events for both UKONS and other organisations throughout the year, including the UK Oncology Forum and the Oncology Professional Care Conference, British Hematology Society. International Cancer Nursing Society and the European Oncology Nursing Society.
- Work commenced and continued on a book on the impact of the COVID pandemic in cancer care across Europe in partnership with Springer Press.

Growing forums:

Work continues to take requests from members for forum activity:

Practice Educator Forum:

- Ongoing 4-6 weekly forums online
- Webinar x1

Champions Forum:

- Cancer and domestic Abuse Kit
- Breaking News
- Supporting conference Stands
- Assist in chairing the conference sessions

Lead Nurse Forum:

- In-person meeting
- Two online (half day)
- Membership continues to increase with good peer support & networking
- Closed Facebook page

Young and Early Career Forum (YECC):

- Co-opted board members
- Annual online webinar

Partnership working: .

- Continued to work with a wide range of industry partners and develop further relationships, extending our numbers of partners to more than 20.
- Collaborated with: NHS England, UK Oncology Forum; British Journal of Nursing; Cancer Nursing Practice, The European Oncology Nursing Society (EONS); International Society of Nurses in Cancer Care (ISNCC); Royal Collage of Nursing.
- Representation at the UK Chemotherapy Board; various NHS Working Groups (including those on SACT Capacity and Workforce); Macmillan Cancer Support/HEE.
- Provision of basic oncology education continues to be provided by O'Hallaran Consultancy, to all UKONS members.
- Collaboration with Macmillan Cancer Support to provide Podcasting on topical issues available through podcasting platforms and accessible worldwide.

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

Organisational Structure

The Board has five executive officers: President, President Elect, Past President, Secretary and Treasurer. It has an additional ten full Board members who are all Trustees. New Trustees receive induction into their role on the Board.

Assessment of going concern

The charity's income is reliant on sponsorship from UKONS Partners. Income for 24/25 was reduced from the previous year but not significantly. It continues to be unpredictable for some partners and their budget constraints. The board maintain a cautious approach and these factors have been considered in budgeting resources for the next financial year.

Directors and Trustees

The directors and trustees who served the company during the year and up to the date of this report were as follows:

Karen Campbell (President)
Mary Tanay (President Elect)
Mark Foulkes (Past President)
Lyndel Moore (Treasurer)
Jo Bird (Secretary - appointed 4 December 2024)
Kay Bell (resigned 4 December 2024)
Rachel Bryce (appointed 4 December 2024)
Naomi Clatworthy
Jane Ewang (appointed 4 December 2024)
Ruth Hammond
Nicola Jones (appointed 4 December 2024)
Nalayini Kumaralingam (resigned 5 December 2024)
Bethany Maynard (appointed 4 December 2024)
Barry Quinn
Rosemary Roberts (resigned 4 December 2024)
Constance Rowell
Linda Sherwood
Tracy Wilson
Debbie Wightman (resigned 4 December 2024)

Reserves

The Trustees plan to retain a modest level of reserves as a contingency fund against future demands on the charity's resources.

Small Company Provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Signed on behalf of the directors

DocuSigned by:
Karen Campbell
BA8F1726C53B49B...

Dr Karen Campbell
Director

Approved on 03 September 2025

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Independent Examiner's Report to the Trustees

Year Ended 31 March 2025

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2025.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed by:
Martin Hobbs
342D60FB7F7A405...

Martin Hobbs BSc ACA
Francis Clark LLP
Chartered Accountants
Sigma House
Oak View Close
Edginswell Park
Torquay
TQ2 7FF

Date: 04 September 2025

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Statement of Financial Activities (incorporating an Income and Expenditure Account)

Year Ended 31 March 2025

	Unrestricted Funds £	Restricted Funds £	Total 2025 £	Total 2024 £
Income from:				
Partnership income	130,500	-	**130,500**	147,042
Board activity	5,885	-	**5,885**	19,235
Donations	-	-	**-**	1,408
Grants	-	-	**-**	40,000
Other income	-	-	**-**	16,667
Total	136,385	-	**136,385**	224,352
Expenditure on:				
BJN Awards	27	-	**27**	277
CASCADE workshop	-	-	**-**	2,111
Covid 19 and Cancer book	-	-	**-**	11,402
Personalised Cancer Care Book	-	-	**-**	4,000
Pocketbook of Cancer Care Nursing	-	-	**-**	8,333
Cytotoxic Drug Exposure Research Grant	13,348	-	**13,348**	-
SACT passport project	16,244		**16,244**	58,435
EBN Health book	-	-	**-**	2,917
Palliative care booklet	-	-	**-**	-
EONS membership fee	835	-	**835**	875
ISNCC membership fee	494	-	**494**	248
Annual conference	19,112	-	**19,112**	38,122
Board meetings – Travel and subsistence	6,464	-	**6,464**	7,784
Other conferences	927	-	**927**	14,634
Entertaining/other meetings	2,116	-	**2,116**	14,346
MIGs	5,509	-	**5,509**	8,202
Administrative support	21,600	-	**21,600**	26,760
Secretarial services	15,000	-	**15,000**	15,000
Legal and professional	795	-	**795**	660
Stationery and admin	-	-	**-**	186
Website and social media	8,091	-	**8,091**	7,043
Accounting fees	10,744	-	**10,744**	10,320
Insurance	1,068	-	**1,068**	985
Irrecoverable VAT	8,174	-	**8,174**	10,997
Grants BMS AOS	484	-	**484**	36,485
Purchases	325	-	**325**	10,734
Total	131,357	-	**131,357**	290,856
Net income/(expenditure)	**5,028**	**-**	**5,028**	(66,504)
Total funds brought forward	122,303	-	122,303	188,807
Total funds carried forward	**127,331**	**-**	**127,331**	122,303

All of the incoming resources of the charity for the comparative year are unrestricted. All of the above results are derived from continuing activities. All gains and losses recognised in the year are included above. The result for the year for Companies Act purposes is equivalent to the net income / (expenditure).

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Balance Sheet

31 March 2025

	Notes	2025 £	2024 £
Current assets			
Debtors	**4**	**55,827**	53,095
Cash at bank and in hand		**189,265**	151,808
		245,092	204,903
Liabilities			
Creditors falling due within one year	**5**	**(117,761)**	(82,600)
Total assets less current liabilities		**127,331**	122,303
Unrestricted funds	**6**	**127,331**	122,303
Restricted funds	**6**	**-**	-
Total funds		**127,331**	122,303

The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the financial statements for the year by virtue of section 477, and that no member or members have requested an audit pursuant to section 476 of the Act.

The directors acknowledge their responsibilities for:

(i) ensuring that the company keeps adequate accounting records which comply with section 386 of the Act, and

(ii) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the financial year in accordance with the requirements of sections 394 and 395, and which otherwise comply with the requirements of the Act relating to financial statements, so far as is applicable to the company.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act.

These financial statements were approved and signed by the trustees and authorised for issue on 03 September 2025 , and are signed on their behalf by:

DocuSigned by:
Karen Campbell
BA8F1726C53B49B...
Karen Campbell
Director

Company Registration Number: 06996552

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

The UK Oncology Nursing Society

Notes to the Financial Statements

Year Ended 31 March 2025

1 Accounting Policies

Basis of accounting

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation of financial statements and assessment of going concern

The financial statements have been prepared under the historical cost convention and in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The UK Oncology Nursing Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The functional and presentational currency of these financial statements is sterling.

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

b) Income

Income is recognised when the charity has entitlement to funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Capital grants receivable are credited to the SOFA as they become receivable and are treated as restricted funds. The depreciation on the assets to which the grants relate is charged against these funds.

c) Fund accounting

Unrestricted funds are funds available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds received which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes.

d) Expenditure

Expenditure is recognised once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure includes irrecoverable VAT.

e) Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. The company holds the following financial instruments, all of which are considered to be basic:

- Short term debtors and creditors
- Cash and bank balances

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

2 Related Party Transactions

During the year travel expenses of £3,270 were reimbursed to 12 trustees (2024: £11,919 to 13 trustees).

3 Company Limited by Guarantee

The company is limited by guarantee and has no share capital. In the event of a winding-up, the liability of the members is limited to £1 each. The Charity is incorporated in England and Wales. The address of its registered office is: Office 605, Albert House, 256-260 Old St, London EC1V 9DD.

4 Debtors

	2025 £	2024 £
Trade debtors	**49,294**	40,702
Prepayments and accrued income	**6,533**	5,599
VAT	**-**	6,794
	55,827	53,095

5 Creditors: amounts falling due within one year

	2025 £	2024 £
Accruals and deferred income	**106,905**	82,600
VAT payable	**10,856**	-
Other creditors	**-**	-
	117,761	82,600

6 Analysis of movement in funds

	Balance at 1 April 2024 £	Incoming resources £	Resources expended £	Balance at 31 March 2025 £
Total unrestricted funds	122,303	136,385	(131,357)	**127,331**
	122,303	136,385	(131,357)	**127,331**

Docusign Envelope ID: 49C915B9-A422-480E-9C73-691226D84312

6 Analysis of movement in funds (continued)

Prior year analysis of movement in funds

	Balance at 1 April 2023 £	Incoming resources £	Resources expended £	Balance at 31 March 2024 £
Total unrestricted funds	183,660	184,352	(245,709)	**122,303**
Restricted funds:				
Gilead	-	5,000	(5,000)	**-**
BMS	-	35,000	(35,000)	**-**
AOS education grant	2,230	-	(2,230)	**-**
EBN book grant	2,917	-	(2,917)	**-**
	188,807	224,352	(290,856)	**122,303**

The Gilead grant represents funds to support healthcare professionals to attend the UKONS 2023 conference.

The BMS AOS grant represents funds raised towards the development of acute oncology service telephone triage E-learning modules

The AOS education grant represents funds raised for the development of a digital friendly format for UKONS guidance for assessment of patients.

The EBN book grant represents funds raised for the writing and publication of a reference book entitled “Fundamentals of Cancer Care”.

The restricted funds are all held as cash at bank and in hand.

THE UK ONCOLOGY NURSING SOCIETY

England & Wales - Charity number 1136972

Accounts

The trustees have pleasure in presenting their report and the unaudited financial statements of the charitable company for the year ended 31 March 2024.

Status

The charitable company is limited by guarantee, having no share capital. Under the provisions of Section 60 of the Companies Act 2006, the company is entitled to omit the word "Limited" from its name. The governing document of the charitable company is its Memorandum and Articles of Association.

The charitable company is also known as UKONS.

Objects and Activities of the Charity

The objects of the charitable company are, for the public benefit:

1. To advance health and to relieve those in need by reason of ill-health, including without limitation people affected by cancer; and

2. To advance the education of the public in the subjects of health, medical and nursing care, including without limitation the causes, effects and treatments of cancer.

Aims of the charity

- To promote excellence in the nursing care and management of all those directly and indirectly affected by cancer.
- To encourage and facilitate the personal and professional development of nurses engaged in cancer care throughout the UK and overseas through education, research and policy.
- To share information about research, learning and development opportunities with UKONS members.
- To contribute to the development of cancer policy, clinical practice and service delivery nationally and internationally.
- To foster alliances and develop UK and international networking opportunities.

Activities and achievements aligned to the charity's aims for the year 202/24

- Continuation of the Members Interest Groups: Living with and Beyond Cancer; Acute Oncology Services; Systemic Anti-cancer Treatments; Radiotherapy; Haemato-oncology; Lead Cancer Nurses; Research
- A further Members Interest Group- 'Young and Early Career Cancer Nurses' was added in 2021 and fully established as an interest group with annual webinar activity and a Facebook and social media presence.
- Continuation of our provision of the UKONS website (www.ukons.org), catering to the needs of members and the members interest groups.
- Continued publication of fortnightly editions of UKONS 'Breaking News' bulletin, supporting practice development and career progression, which is sent to all members via e-mail. This includes cancer nurse job advertisements for UKONS members. These advertisements are provided free of charge to advertisers.
- During 2023/24 Breaking News continued to be delivered jointly between UKONS and Macmillan Cancer Care due to an ongoing and developing partnership. This was underpinned by an MOU agreed and signed by both parties, renewed in 2022.
- UKONS continues to hold the face-to-face annual conference since with increasing numbers of abstract submissions and attendance. The event focussed on a theme of 'Integrating Cancer Care'. This provided the opportunity for cancer nurses to present orally, and through posters on education, innovation and research. This year, as with the previous nine, the

conference abstract booklet was made available to delegates. This is available in electronic format.

- Work continued to produce a digital application of the UKONS Systemic Anti-cancer Therapy (SACT) Competency Passport together with our partner is Tefogo Ltd. This was launched in January 2024.
- During 2023/24 UKONS continued to be a prominent member of the UK SACT Board (formally UK Chemotherapy Board) delivering guidelines across all four nations for the delivery of systemic anti-cancer therapies.
- UKONS continued to be a central organisation in promoting the ACCEND (Aspirant Cancer Career and Education Development) programme. This career framework provides guidance and structure or all health care professionals wishing to develop a career in cancer care.
- Continued to approve translations of the UKONS Acute Oncology Triage Tool as well as working to formalise and deliver electronic versions of the tool.
- The AOS interest group designed and developed an eLearning course in partnership with E learning for Health NHS England. This was launched in 2024.
- UKONS worked in partnership with the UK Acute Oncology Society and Macmillan to standardise AO education, training and assessment and advanced work on multi-professional AO competency passports. To be launched in June 2024
- Work commenced and continued on a book on the impact of the COVID pandemic in cancer care across Europe in partnership with Springer Press.
- Organised and presented education, training sessions and symposia at virtual and face-to-face events for both UKONS and other organisations throughout the year, including the UK Oncology Forum and the Oncology Professional Care Conference, British Hematology Society. International Cancer Nursing Society and the European Oncology Nursing Society.
- Further developed the activities of UKONS Champions, with Young and Early Career Cancer Nurse input into a wide range of programmes and events. The champions worked to establish a sub-group for both UKONS board alumni and Cancer Information Nurses.
- Continued to work with a wide range of industry partners and develop further relationships, extending our numbers of partners to more than 20.
- Collaborated with: NHS England, UK Oncology Forum; British Journal of Nursing; Cancer Nursing Practice, The European Oncology Nursing Society (EONS); International Society of Nurses in Cancer Care (ISNCC); and Oncology Professional Care
- Representation at the UK Chemotherapy Board; various NHS Working Groups (including those on SACT Capacity and Workforce); Macmillan Cancer Support/HEE.
- Provision of basic oncology education provided by O'Hallaran Consultancy, to all UKONS members.
- Collaboration with Macmillan Cancer Support to provide Podcasting on topical issues available through podcasting platforms and accessible worldwide.

Organisational Structure

The Board has five executive officers: President, President Elect, Past President Secretary and Treasurer. It has an additional ten full Board members who are all Trustees. New Trustees receive induction into their role on the Board.

Assessment of going concern

The charity's income is reliant on sponsorship from UKONS Partners. Income for 23/24 was reduced from the previous year but not significantly. It continues to be unpredictable for some partners and their budget constraints. The board maintain a cautious approach and these factors have been considered in budgeting resources for the next financial year.

Directors and Trustees

The directors and trustees who served the company during the year and up to the date of this report were as follows:
Karen Campbell (President)
Mary Tanay (President Elect)
Mark Foulkes (Past President)
Lyndel Moore (Treasurer)
Deborah Wightman (Secretary)
Nalayini Kumaralingam
Kay Bell
Jo Bird
Tracy Wilson
Rosemary Roberts
Naomi Clatworthy
Ruth Hammond
Constance Rowell
Barry Quinn
Linda Sherwood

Reserves

The Trustees plan to retain a modest level of reserves as a contingency fund against future demands on the charity's resources.

Small Company Provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Signed on behalf of the directors



Dr Karen Campbell
Director

Approved on ……31st August 2024

The UK Oncology Nursing Society

Unaudited Financial Statements

Year Ended 31 March 2024

Company Registration Number 06996552
Charity Registration Number 1136972

The UK Oncology Nursing Society

Financial Statements

Year Ended 31 March 2024

Contents **Page**

Trustees' Report	1
Independent Examiner’s Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7

The UK Oncology Nursing Society

Trustees' Report

Year Ended 31 March 2024

The trustees have pleasure in presenting their report and the unaudited financial statements of the charitable company for the year ended 31 March 2024.

Status

The charitable company is limited by guarantee, having no share capital. Under the provisions of Section 60 of the Companies Act 2006, the company is entitled to omit the word "Limited" from its name. The governing document of the charitable company is its Memorandum and Articles of Association.

The charitable company is also known as UKONS.

Objects and Activities of the Charity

The objects of the charitable company are, for the public benefit:

1. To advance health and to relieve those in need by reason of ill-health, including without limitation people affected by cancer; and

2. To advance the education of the public in the subjects of health, medical and nursing care, including without limitation the causes, effects and treatments of cancer.

Aims of the charity

- To promote excellence in the nursing care and management of all those directly and indirectly affected by cancer.
- To encourage and facilitate the personal and professional development of nurses engaged in cancer care throughout the UK and overseas through education, research and policy.
- To share information about research, learning and development opportunities with UKONS members.
- To contribute to the development of cancer policy, clinical practice and service delivery nationally and internationally.
- To foster alliances and develop UK and international networking opportunities.

Activities and achievements aligned to the charity's aims for the year 2023/24

- Continuation of the Members Interest Groups: Living with and Beyond Cancer; Acute Oncology Services; Systemic Anti-cancer Treatments; Radiotherapy; Haemato-oncology; Lead Cancer Nurses; Research
- A further Members Interest Group- 'Young and Early Career Cancer Nurses' was added in 2021 and fully established as an interest group with annual webinar activity and a Facebook and social media presence.
- Continuation of our provision of the UKONS website (www.ukons.org), catering to the needs of members and the members interest groups.
- Continued publication of fortnightly editions of UKONS 'Breaking News' bulletin, supporting practice development and career progression, which is sent to all members via e-mail. This includes cancer nurse job advertisements for UKONS members. These advertisements are provided free of charge to advertisers.
- During 2023/24 Breaking News continued to be delivered jointly between UKONS and Macmillan Cancer Care due to an ongoing and developing partnership. This was underpinned by an MOU agreed and signed by both parties, renewed in 2022.
  UKONS continues to hold the face-to-face annual conference since with increasing numbers of abstract submissions and attendance. The event focussed on a theme of 'Integrating Cancer Care'. This provided the opportunity for cancer nurses to present orally, and through posters on

education, innovation and research. This year, as with the previous nine, the conference abstract booklet was made available to delegates. This is available in electronic format. Work continued to produce a digital application of the UKONS Systemic Anti-cancer Therapy (SACT) Competency Passport together with our partner is Tefogo Ltd. This was launched in January 2024.

- During 2023/24 UKONS continued to be a prominent member of the UK SACT Board (formally UK Chemotherapy Board) delivering guidelines across all four nations for the delivery of systemic anti-cancer therapies.
- UKONS continued to be a central organisation in promoting the ACCEND (Aspirant Cancer Career and Education Development) programme. This career framework provides guidance and structure or all health care professionals wishing to develop a career in cancer care.
- Continued to approve translations of the UKONS Acute Oncology Triage Tool as well as working to formalise and deliver electronic versions of the tool.
- The AOS interest group designed and developed an eLearning course in partnership with E learning for Health NHS England. This was launched in 2024.
- UKONS worked in partnership with the UK Acute Oncology Society and Macmillan to standardise AO education, training and assessment and advanced work on multi-professional AO competency passports. To be launched in June 2024
- Work commenced and continued on a book on the impact of the COVID pandemic in cancer care across Europe in partnership with Springer Press.
- Organised and presented education, training sessions and symposia at virtual and face-to-face events for both UKONS and other organisations throughout the year, including the UK Oncology Forum and the Oncology Professional Care Conference, British Hematology Society. International Cancer Nursing Society and the European Oncology Nursing Society.
- Further developed the activities of UKONS Champions, with Young and Early Career Cancer Nurse input into a wide range of programmes and events. The champions worked to establish a sub-group for both UKONS board alumni and Cancer Information Nurses.
- Continued to work with a wide range of industry partners and develop further relationships, extending our numbers of partners to more than 20.
- Collaborated with: NHS England, UK Oncology Forum; British Journal of Nursing; Cancer Nursing Practice, The European Oncology Nursing Society (EONS); International Society of Nurses in Cancer Care (ISNCC); and Oncology Professional Care
- Representation at the UK Chemotherapy Board; various NHS Working Groups (including those on SACT Capacity and Workforce); Macmillan Cancer Support/HEE.
- Provision of basic oncology education provided by O'Hallaran Consultancy, to all UKONS members.
- Held the European Cancer Nursing Day in Edinburgh 2023 in collaboration with EONS.
- Collaboration with Macmillan Cancer Support to provide Podcasting on topical issues available through podcasting platforms and accessible worldwide.

Organisational Structure

The Board has five executive officers: President, President Elect, Past President Secretary and Treasurer. It has an additional ten full Board members who are all Trustees. New Trustees receive induction into their role on the Board.

Assessment of going concern

The charity's income is reliant on sponsorship from UKONS Partners. Income for 23/24 has increased from the previous year. Income continues to be unpredictable for some partners and their budget constraints. The board maintain a cautious approach and these factors have been considered in budgeting resources for the next financial year.

Directors and Trustees

The directors and trustees who served the company during the year and up to the date of this report were as follows:

Karen Campbell (President Elect) (from 17 November 2023)
Mary Tanay
Mark Foulkes (Past President) (to 16 November 2023)
Lyndel Moore (Treasurer)
Deborah Wightman (Trustee and Secretary)
Nalayini Kumaralingam
Kay Bell
Jo Bird
Tracy Wilson
Rosemary Roberts
Naomi Clatworthy
Ruth Hammond
Constance Rowell
Verna Lavender (resigned 17 November 2023)
Barry Gerard Quinn (appointed 18 November 2023)
Linda Sherwood (appointed 18 November 2023)
Lisa Barrott (resigned 17 November 2023)
Libby Potter (resigned 31 January 2024)

Reserves

The Trustees plan to retain a modest level of reserves as a contingency fund against future demands on the charity's resources.

Small Company Provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Signed on behalf of the directors



Dr Karen Campbell
Director

Approved on 30 November 2024

The UK Oncology Nursing Society

Independent Examiner's Report to the Trustees

Year Ended 31 March 2024

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2024.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Martin Hobbs BSc ACA
Francis Clark LLP
Chartered Accountants
Sigma House
Oak View Close
Edginswell Park
Torquay
TQ2 7FF

Date: 2 December 2024

The UK Oncology Nursing Society

Statement of Financial Activities (incorporating an Income and Expenditure Account)

Year Ended 31 March 2024

	Unrestricted Funds £	Restricted Funds £	Total 2024 £	Total 2023 £
Income from:				
Partnership income	147,042	-	**147,042**	80,833
Board activity	19,235	-	**19,235**	14,691
Donations	1,408	-	**1,408**	4,100
Grants	-	40,000	**40,000**	**-**
Other income	16,667	-	**16,667**	1,025
Total	184,352	40,000	**224,352**	100,649
Expenditure on:				
BJN Awards	277	-	**277**	-
CASCADE workshop	2,111	-	**2,111**	-
Covid 19 and Cancer book	11,402	-	**11,402**	-
Personalised Cancer Care Book	4,000	-	**4,000**	-
Pocketbook of Cancer Care Nursing	8,333	-	**8,333**	-
SACT passport project	56,205	2,230	**58,435**	20,000
Champions' workshop	-	-	**-**	31
EBN Health book	-	2,917	**2,917**	28
Palliative care booklet	-	-	**-**	2,450
EONS membership fee	875	-	**875**	893
ISNCC membership fee	248	-	**248**	244
Annual conference	33,122	5,000	**38,122**	22,500
Board meetings – Travel and subsistence	7,784	-	**7,784**	8,970
Other conferences	14,634	-	**14,634**	11,084
Entertaining/other meetings	14,346	-	**14,346**	11,055
MIGs	8,202	-	**8,202**	7,629
Administrative support	26,760	-	**26,760**	15,760
Secretarial services	15,000	-	**15,000**	330
Legal and professional	660	-	**660**	2,601
Stationery and admin	186	-	**186**	17
Website and social media	7,043	-	**7,043**	7,013
Accounting fees	10,320	-	**10,320**	5,475
Insurance	985	-	**985**	848
Irrecoverable VAT	10,997	-	**10,997**	6,931
Grants BMS AOS	1,485	35,000	**36,485**	15,000
Purchases	10,734	-	**10,734**	10,230
Total	245,709	45,147	**290,856**	149,089
Net income/(expenditure)	**(61,357)**	**(5,147)**	**(66,504)**	(48,440)
Total funds brought forward	183,660	5,147	188,807	237,247
Total funds carried forward	**122,303**	**-**	**122,303**	188,807

All of the incoming resources of the charity for the comparative year are unrestricted. All of the above results are derived from continuing activities. All gains and losses recognised in the year are included above. The result for the year for Companies Act purposes is equivalent to the net income / (expenditure).

The UK Oncology Nursing Society

Balance Sheet

31 March 2024

	Notes	2024 £	2023 £
Current assets			
Debtors	**4**	**53,095**	22,120
Cash at bank and in hand		**151,808**	252,811
		204,903	274,931
Liabilities			
Creditors falling due within one year	**5**	**(82,600)**	(86,124)
Total assets less current liabilities		**122,303**	188,807
Unrestricted funds	**6**	**122,303**	183,660
Restricted funds	**6**	**-**	5,147
Total funds		**122,303**	188,807

The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the financial statements for the year by virtue of section 477, and that no member or members have requested an audit pursuant to section 476 of the Act.

The directors acknowledge their responsibilities for:

(i) ensuring that the company keeps adequate accounting records which comply with section 386 of the Act, and

(ii) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the financial year in accordance with the requirements of sections 394 and 395, and which otherwise comply with the requirements of the Act relating to financial statements, so far as is applicable to the company.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act.

These financial statements were approved and signed by the trustees and authorised for issue on 30 November 2024, and are signed on their behalf by:



……..
Karen Campbell
Director

Company Registration Number: 06996552

1 Accounting Policies

Basis of accounting

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation of financial statements and assessment of going concern

The financial statements have been prepared under the historical cost convention and in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The UK Oncology Nursing Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The functional and presentational currency of these financial statements is sterling.

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

b) Income

Income is recognised when the charity has entitlement to funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Capital grants receivable are credited to the SOFA as they become receivable and are treated as restricted funds. The depreciation on the assets to which the grants relate is charged against these funds.

c) Fund accounting

Unrestricted funds are funds available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds received which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes.

d) Expenditure

Expenditure is recognised once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure includes irrecoverable VAT.

e) Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. The company holds the following financial instruments, all of which are considered to be basic:

- Short term debtors and creditors
- Cash and bank balances

2 Related Party Transactions

During the year travel expenses of £11,919 were reimbursed to 13 trustees (2023: £12,164 to 15 trustees).

3 Company Limited by Guarantee

The company is limited by guarantee and has no share capital. In the event of a winding-up, the liability of the members is limited to £1 each. The Charity is incorporated in England and Wales. The address of its registered office is: Legalinx, 14-18 City Road, Cardiff, Wales, CF24 3DL.

4 Debtors

	2024 £	2023 £
Trade debtors	**40,702**	20,005
Prepayments and accrued income	**5,599**	2,115
VAT	**6,794**	-
	53,095	22,120

5 Creditors: amounts falling due within one year

	2024 £	2023 £
Accruals and deferred income	**82,600**	62,059
VAT payable	**-**	3,709
Other creditors	**-**	20,356
	82,600	86,124

6 Analysis of movement on funds

	Balance at 1 April 2023 £	Incoming resources £	Resources expended £	Balance at 31 March 2024 £
Total unrestricted funds	183,660	184,352	(245,709)	**122,303**
Restricted funds:				
Gilead	-	5,000	(5,000)	-
BMS	-	35,000	(35,000)	-
AOS education grant	2,230	-	(2,230)	**-**
EBN book grant	2,917	-	(2,917)	**-**
	188,807	224,352	(290,856)	**122,303**

The Gilead grant represents funds to support healthcare professionals to attend the UKONS 2023 conference

The BMS AOS grant represents funds raised towards the development of acute oncology service telephone triage E-learning modules

The AOS education grant represents funds raised for the development of a digital friendly format for UKONS guidance for assessment of patients.

The EBN book grant represents funds raised for the writing and publication of a reference book entitled "Fundamentals of Cancer Care".

The restricted funds are all held as cash at bank and in hand.

Prior year analysis of movement on funds

	Balance at 1 April 2022 £	Incoming resources £	Resources expended £	Balance at 31 March 2023 £
Total unrestricted funds	232,072	100,649	(149,061)	**183,660**
Restricted funds:				
AOS education grant	2,230	-	-	**2,230**
EBN book grant	2,945	-	(28)	**2,917**
	237,247	100,649	(149,089)	**188,807**

.

The AOS education grant represents funds raised for the development of a digital friendly format for UKONS guidance for assessment of patients.

The EBN book grant represents funds raised for the writing and publication of a reference book entitled "Fundamentals of Cancer Care".

The restricted funds are all held as cash at bank and in hand.

UK Oncology Nursing Society

Corporation Tax Computation

Year ended 31 March 2024

Tax reference: 456 98149 27182

UK Oncology Nursing Society
Year ended 31 March 2024

Contents

Corporation tax computation

A1 Corporation tax

Accounts analysis

B1 Profit and loss account reconciliation

Additional e-filing disclosures

C1 CT600 return values

A1 Corporation tax

	Tax
	£
Corporation tax payable	nil

B1 Profit and loss account reconciliation

	£
Profit per accounts	nil

UK Oncology Nursing Society
Year ended 31 March 2024

C1 **CT600 return values**

	CT600 box	£
Profits before deductions and reliefs		
Profits before other deductions and reliefs	235	-
Profits chargeable to corporation tax	315	nil
Tax calculation		
Corporation tax	430	-
Corporation tax chargeable	440	-
Calculation of tax outstanding or overpaid		
Self-assessment of tax payable before restitution tax and coronavirus support scheme overpayments	525	-
Self-assessment of tax payable	528	nil

HM Revenue & Customs

Company Tax Return

CT600 (2024) Version 3

for accounting periods starting on or after 1 April 2015

Your Company Tax Return

If we send the company a 'Notice' to deliver a Company Tax Return it has to comply by the filing date or we charge a penalty, even if there is no tax to pay.

A return includes a Company Tax Return form, any supplementary pages, accounts, computations and any relevant information. The CT600 Guide tells you how the return must be formatted and delivered. It contains general information you may need to deliver your return, links to more detailed advice and box-by-box guidance for this form and the supplementary pages.

The forms in the CT600 series set out the information we need and provide a standard format for calculations.

Company information

1	Company name	UK Oncology Nursing Society
2	Company registration number	06996552
3	Tax reference	9814927182
4	Type of company	8

Northern Ireland (NI)

Put an 'X' in the appropriate boxes below

5	NI trading activity		6	SME	
7	NI employer		8	Special circumstances	

About this return

This is the tax return for the company named above, for the period below

30	from DD MM YYYY	01 04 2023	
35	to DD MM YYYY	31 03 2024	

Put an 'X' in the appropriate boxes below

40	A repayment is due for this return period	
45	Claim or relief affecting an earlier period	
50	Making more than one return for this company now	
55	This return contains estimated figures	
60	Company part of a group that is not small	
65	Notice of disclosable avoidance schemes	
	Transfer pricing	
70	Compensating adjustment claimed	
75	Company qualifies for SME exemption	

UK Oncology Nursing Society

About this return - continued

Accounts and computations

80	**I attach accounts and computations for the period to which this return relates**	X
85	**I attach accounts and computations for a different period**	
90	**If you're not attaching the accounts and computations, explain why**	

Supplementary pages enclosed

95	**Loans and arrangements to participators by close companies** - form CT600A	
100	**Controlled foreign companies, foreign permanent establishment exemptions, hybrid and other mismatches** - form CT600B	
105	**Group and consortium** - form CT600C	
110	**Insurance** - form CT600D	
115	**Charities and Community Amateur Sports Clubs (CASCs)** - form CT600E	X
120	**Tonnage tax** - form CT600F	
125	**Northern Ireland** - form CT600G	
130	**Cross-border royalties** - form CT600H	
135	**Supplementary charge in respect of ring fence trades** - form CT600I	
140	**Disclosure of Tax Avoidance Schemes** - form CT600J	
141	**Restitution tax** - form CT600K	
142	**Research and Development** - form CT600L	
143	**Freeports and Investment Zones** - form CT600M	
144	**Residential Property Developer Tax (RPDT)** - form CT600N	

Tax calculation - Turnover

145	**Total turnover from trade**	£ . 0 0
150	**Banks, building societies, insurance companies and other financial concerns** - put an 'X' in this box if you do not have a recognised turnover and have not made an entry in box 145	

Income

155	**Trading profits**	£ . 0 0
160	**Trading losses brought forward set against trading profits**	£ . 0 0
165	**Net trading profits** - box 155 minus box 160	£ . 0 0
170	**Bank, building society or other interest, and profits from non-trading loan relationships**	£ . 0 0
172	**Put an 'X' in box 172 if the figure in box 170 is net of carrying back a deficit from a later accounting period**	

UK Oncology Nursing Society

Income - continued

175	**Annual payments not otherwise charged to Corporation Tax and from which Income Tax has not been deducted**	£ . 0 0
180	**Non-exempt dividends or distributions from non-UK resident companies**	£ . 0 0
185	**Income from which Income Tax has been deducted**	£ . 0 0
190	**Income from a property business**	£ . 0 0
195	**Non-trading gains on intangible fixed assets**	£ . 0 0
200	**Tonnage tax profits**	£ . 0 0
205	**Income not falling under any other heading**	£ . 0 0

Chargeable gains

210	**Gross chargeable gains**	£ . 0 0
215	**Allowable losses including losses brought forward**	£ . 0 0
220	**Net chargeable gains** - box 210 minus box 215	£ . 0 0

Profits before deductions and reliefs

225	**Losses brought forward against certain investment income**	£ . 0 0
230	**Non-trade deficits on loan relationships (including interest) and derivative contracts (financial instruments) brought forward set against non-trading profits**	£ . 0 0
235	**Profits before other deductions and reliefs –** net sum of boxes 165 to 205 and 220 minus sum of boxes 225 and 230	£ 0 . 0 0

Deductions and reliefs

240	**Losses on unquoted shares**	£ . 0 0
245	**Management expenses**	£ . 0 0
250	**UK property business losses for this or previous accounting period**	£ . 0 0
255	**Capital allowances for the purposes of management of the business**	£ . 0 0
260	**Non-trade deficits for this accounting period from loan relationships and derivative contracts (financial instruments)**	£ . 0 0

UK Oncology Nursing Society

Deductions and Reliefs - continued

263	**Carried forward non-trade deficits from loan relationships and derivative contracts (financial instruments)**	£ . 0 0
265	**Non-trading losses on intangible fixed assets**	£ . 0 0
275	**Total trading losses of this or a later accounting period**	£ . 0 0
280	**Put an 'X' in box 280 if amounts carried back from later accounting periods are included in box 275**	
285	**Trading losses carried forward and claimed against total profits**	£ . 0 0
290	**Non-trade capital allowances**	£ . 0 0
295	**Total of deductions and reliefs** – total of boxes 240 to 275, 285 and 290	£ . 0 0
300	**Profits before qualifying donations and group relief** – box 235 minus box 295	£ 0 . 0 0
305	**Qualifying donations**	£ . 0 0
310	**Group relief**	£ . 0 0
312	**Group relief for carried forward losses**	£ . 0 0
315	**Profits chargeable to Corporation Tax** – box 300 minus boxes 305, 310 and 312	£ 0 . 0 0
320	**Ring fence profits included**	£ . 0 0
325	**Northern Ireland profits included**	£ . 0 0

Tax calculation

326	**Number of associated companies in this period**	
327	**Number of associated companies in the first financial year**	
328	**Number of associated companies in the second financial year**	
329	**Put an 'X' in box 329 if the company is chargeable at the small profit rate or is entitled to marginal relief**	

Enter how much profit has to be charged and at what rate

	Financial year (yyyy)		Amount of profit		Rate of tax %		Tax	
330		335	£	340		345	£	p
		350	£	355		360	£	p
		365	£	370		375	£	p
380		385	£	390		395	£	p
		400	£	405		410	£	p
		415	£	420		425	£	p

Tax calculation - continued

Corporation Tax - total of boxes 345, 360, 375, 395, 410 and 425	430	£ 0.00
Marginal relief	435	£
Corporation Tax chargeable - box 430 minus box 435	440	£ 0.00

Reliefs and deductions in terms of tax

445	**Community Investment Tax Relief**	£
450	**Double Taxation Relief**	£
455	**Put an 'X' in box 455 if box 450 includes an underlying rate relief claim**	
460	**Put an 'X' in box 460 if box 450 includes an amount carried back from a later period**	
465	**Advance Corporation Tax**	£
470	**Total reliefs and deduction in terms of tax** - total of boxes 445, 450 and 465	£

Coronavirus support schemes and overpayments (see CT600 Guide for definitions)

471	**Coronavirus Job Retention Scheme (CJRS) received**	£
472	**CJRS entitlement**	£
473	**CJRS overpayment already assessed or voluntary disclosed**	£
474	**Other coronavirus overpayments**	£

Energy levies

986	**Energy (Oil and Gas) Profits Levy (EOGPL) amounts liable**	£ 0.00
987	**Electricity Generator Levy (EGL) exceptional generation receipts**	£ 0.00

Calculation of tax outstanding or overpaid

475	**Net Corporation Tax liability** - box 440 minus box 470	£ 0.00
480	**Tax payable on loans and arrangements to participators**	£
485	**Put an 'X' in box 485 if you completed box A70 in the supplementary pages CT600A**	
490	**Controlled Foreign Companies (CFC) tax payable**	£
495	**Bank levy payable**	£
496	**Bank surcharge payable**	£
497	**Residential Property Developer Tax (RPDT) payable**	£

UK Oncology Nursing Society

Calculation of tax outstanding or overpaid - continued

500	**CFC tax, bank levy, bank surcharge and RPDT payable** – total of boxes 490, 495, 496 and 497	£ .
501	**EOGPL payable**	£ .
502	**EGL payable**	£ .
505	**Supplementary charge (ring fence trades) payable**	£ .
510	**Tax chargeable** – total of boxes 475, 480, 500, 501, 502 and 505	£ 0 . 0 0
515	**Income Tax deducted from gross income included in profits**	£ .
520	**Income Tax repayable to the company**	£ .
525	**Self-assessment of tax payable before restitution tax and coronavirus support scheme overpayments** – box 510 minus box 515	£ 0 . 0 0
526	**Coronavirus support schemes overpayment now due** – total of boxes 471 and 474 minus boxes 472 and 473	£ .
527	**Restitution tax**	£ .
528	**Self-assessment of tax payable** – total of boxes 525, 526 and 527	£ 0 . 0 0

Tax reconciliation

530	**Research and Development credit**	£ .
535	**(Not currently used)**	£ .
540	**Creatives tax credit**	£ .
545	**Total of Research and Development credit and creative tax credit** – total box 530 to 540	£ .
550	**Land remediation tax credit**	£ .
555	**Life assurance company tax credit**	£ .
560	**Total land remediation and life assurance company tax credit** – total box 550 and 555	£ .
565	**Capital allowances first-year tax credit**	£ .
570	**Surplus Research and Development credits or creative tax credit payable** – box 545 minus box 525	£ .
575	**Land remediation or life assurance company tax credit payable** – total of boxes 545 and 560 minus boxes 525 and 570	£ .

UK Oncology Nursing Society

Tax reconciliation - continued

580	**Capital allowances first-year tax credit payable** – boxes 545, 560 and 565 minus boxes 525, 570 and 575	£ .
585	**Ring fence Corporation Tax included**	£ .
586	**NI Corporation Tax included**	£ .
590	**Ring fence supplementary charge included**	£ .
595	**Tax already paid (and not already repaid)**	£ .
600	**Tax outstanding** – box 525 minus boxes 545, 560, 565 and 595	£ .
605	**Tax overpaid including surplus or payable credits** – total sum of boxes 545, 560, 565 and 595 minus 525	£ .
610	**Group tax refunds surrendered to this company**	£ .
615	**Research and Development expenditure credits surrendered to this company**	£ .

Exporter information

During the return period, did the company export goods and/or services to individuals, enterprises or organisations outside the United Kingdom (UK)?

616 **Yes – goods** ☐ 617 **Yes – services** ☐ 618 **No – neither** ☐

Indicators and information

620	**Franked investment income/Exempt ABGH distributions**	£ . 0 0
625	**Number of 51% group companies**	

Put an 'X' in the relevant boxes, if in the period, the company:

630	**should have made (whether it has or not) instalment payments as a large company under the Corporation Tax (Instalment Payments) Regulations**	☐
631	**should have made (whether it has or not) instalment payments as a very large company under the Corporation Tax (Instalment Payments) Regulations**	☐
635	**is within a group payments arrangement for the period**	☐
640	**has written down or sold intangible assets**	☐
645	**has made cross-border royalty payments**	☐
647	**Eat Out to Help Out Scheme: reimbursed discounts included as taxable income**	£ . 0 0

UK Oncology Nursing Society

Information about enhanced expenditure and tax reliefs

Research and Development (R&D) or creative enhanced expenditure and tax reliefs

650	Put an 'X' in box 650 if the claim is made by a small or medium-sized enterprise (SME), including a SME subcontractor to a large company	
655	Put an 'X' in box 655 if the claim is made by a large company	
656	Put an 'X' in box 656 to confirm that a R&D claim notification form has been submitted	
657	Put an 'X' in box 657 to confirm that an additional information form has been submitted	
659	R&D expenditure qualifying for SME R&D relief	£ . 0 0
660	R&D enhanced expenditure	£ . 0 0
665	Creative qualifying expenditure and/or additional deduction	£ . 0 0
670	R&D and creative enhanced expenditure total box 660 and box 665	£ . 0 0
675	R&D enhanced expenditure of a SME on work subcontracted to it by a large company	£ . 0 0
680	Vaccine research expenditure	£ . 0 0

Land remediation enhanced expenditure

685	Enter the total enhanced expenditure	£ . 0 0

Information about capital allowances and balancing charges/disposal values

Allowances and charges in the calculation of trading profits and losses

	Capital allowances	Balancing charges
Annual investment allowance	690 £	
Full expensing	688 £	689 £
Machinery and plant – super-deduction	691 £	692 £
Machinery and plant – special rate allowance	693 £	694 £
Machinery and plant – special rate pool	695 £	700 £
Machinery and plant – main pool	705 £	710 £
Structures and buildings	711 £	
Business premises renovation	715 £	720 £
Other allowances and charges	725 £	730 £

UK Oncology Nursing Society

Allowances and charges in the calculation of trading profits and losses - continued

	Capital allowances	Disposal value
Electric charge-points	713 £	714 £
Enterprise zones	721 £	722 £
Zero emissions goods vehicles	723 £	724 £
Zero emissions cars	726 £	727 £

Allowances and charges not included in the calculation of trading profits and losses

	Capital allowances	Balancing charges
Annual investment allowance	735 £	
Structures and buildings	736 £	
Full expensing	733 £	734 £
Business premises renovation	740 £	745 £
Machinery and plant – super-deduction	741 £	742 £
Machinery and plant – special rate allowance	743 £	744 £
Other allowances and charges	750 £	755 £

	Capital allowances	Disposal value
Electric charge-points	737 £	738 £
Enterprise zones	746 £	747 £
Zero emissions goods vehicles	748 £	749 £
Zero emissions cars	751 £	752 £

UK Oncology Nursing Society

Qualifying expenditure

760	Machinery and plant on which first year allowance is claimed	£ . 0 0
765	Designated environmentally friendly machinery and plant	£ . 0 0
770	Machinery and plant on long-life assets and integral features	£ . 0 0
771	Structures and buildings	£ . 0 0
772	Machinery and plant – super-deduction	£ . 0 0
773	Machinery and plant – special rate allowance	£ . 0 0
775	Other machinery and plant	£ . 0 0

Losses, deficits and excess amounts

Amount arising

	Amount	Maximum available for surrender as group relief
Losses of trades carried on wholly or partly in the UK	780 £	785 £
Losses of trades carried on wholly outside the UK	790 £	
Non-trade deficits on loan relationships and derivative contracts	795 £	800 £
UK property business losses	805 £	810 £
Overseas property business losses	815 £	
Losses from miscellaneous transactions	820 £	
Capital losses	825 £	
Non-trading losses on intangible fixed assets	830 £	835 £

Excess amounts

	Amount	Maximum available for surrender as group relief
Non-trade capital allowances		840 £
Qualifying donations		845 £
Management expenses	850 £	855 £

UK Oncology Nursing Society

Northern Ireland information

856	Amount of group relief claimed which relates to NI trading losses used against rest of UK/mainstream profits	£ . 0 0
857	Amount of group relief claimed which relates to NI trading losses used against NI trading profits	£ . 0 0
858	Amount of group relief claimed which relates to rest of UK/mainstream losses used against NI trading profits	£ . 0 0

Overpayments and repayments

Small repayments

860 Do not repay sums of £ . 0 0 or less.

Read the overpayments and repayments section of the Company Tax Return Guide for specific guidance on when and how to make an entry in this box.

Repayments for the period covered by this return

865	Repayment of Corporation Tax	£ .
870	Repayment of Income Tax	£ .
875	Payable Research and Development tax credit	£ .
880	Payable Research and Development expenditure credit	£ .
885	Payable creative tax credit	£ .
890	Payable land remediation or life assurance company tax credit	£ .
895	Payable capital allowances first-year tax credit	£ .

Surrender of tax refund within group

Including surrenders under the Instalment Payments Regulations

900 The following amount is to be surrendered £ .

Put an 'X' in the appropriate boxes below

the joint Notice is attached 905

or

will follow 910

915 Please stop repayment of the following amount until we send you the Notice £ .

UK Oncology Nursing Society

Bank details (for a person to whom a repayment is to be made)

920 **Name of bank or building society**

925 **Branch sort code**

930 **Account number**

935 **Name of account**

940 **Building society reference**

Payments to a person other than the company

945 **Complete the authority below if you want the repayment to be made to a person other than the company**
I, as (enter status - for example, company secretary, treasurer, liquidator or authorised agent)

950 **of** (enter company name)

955 **authorise** (enter name)

960 **of address** (enter address)

965 **Nominee reference**

to receive payment on company's behalf

970 **Name**

Declaration

Declaration
I declare that the information I have given on this Company Tax Return and any supplementary pages is correct and complete to the best of my knowledge and belief.

I understand that giving false information in the return, or concealing any part of the company's profits or tax payable, can lead to both the company and me being prosecuted.

975 **Name**
DR K CAMPBELL

980 **Date** DD MM YYYY

985 **Status**
Director

HM Revenue & Customs

Company Tax Return – supplementary page

Charities and Community Amateur Sports Clubs (CASCs)

CT600E (2015) Version 3 for accounting periods starting on or after 1 April 2015

Guidance

Guidance about when and how to complete this supplementary page can be found in the CT600 Guide.

For further information read *What supplementary pages do I need to complete and include as part of the Company Tax Return?* to find out what supplementary pages you need to complete.

Also, read the *Important points about all supplementary pages* and *CT600E - Charities and Community Amateur Sports Clubs (CASCs)* for further guidance about completing this supplementary page.

Company information

E1	**Company name (name of charity or CASC)**	UK Oncology Nursing Society
E2	**Tax reference**	98149 27182

Period covered by this supplementary page (cannot exceed 12 months)

E3	**from** *DD MM YYYY*	01 04 2023
E4	**to** *DD MM YYYY*	31 03 2024

Claims to exemption (this section should be completed in all cases)

	Charity/CASC repayment reference	E5
	Charity Commission registration number, or OSCR number (if applicable)	E10 1136972

Put an 'X' in the relevant box if during the period covered by these supplementary pages:

	The company was a charity/CASC and is claiming exemption from all tax on all or part of its income and gains *(Also put an 'X' in box E15 if the company was a charity/CASC but had no income or gains in the period)*	E15 X
	All income and gains are exempt from tax and have been, or will be, applied for charitable or qualifying purposes only	E20 X
	Some of the income and gains may not be exempt or have not been applied for charitable or qualifying purposes only, and I have completed form CT600	E25

I claim exemption from tax

	Name	E30 DR K CAMPBELL
	Status	E35 Director
	Date *DD MM YYYY*	E40

Repayments

To make a repayment claim for the period covered by these supplementary pages, please register and enrol to use the Charities Online service. See CT600 guide for further information.

Put an 'X' in the box if during the period covered by these supplementary pages you have over claimed tax. E45

Information required

Enter details of any income received from the following sources, claimed as exempt from tax in the hands of the charity/CASC. Enter the figure included in the charity's/CASC'S accounts for the period covered by this return.

Non-exempt amounts should be entered on form CT600 in the appropriate boxes.

Type of income	Amount
Enter total turnover from exempt charitable trading activities	E50 £ .00
Investment income – exclude any amounts included on form CT600	E55 £ .00
UK land and buildings – exclude any amounts included on form CT600	E60 £ .00
Gift Aid – exclude any amounts included on form CT600	E65 £ .00
From other charities – exclude any amounts included on form CT600	E70 £ .00
Gifts of shares or securities received	E75 £ .00
Gifts of real property received	E80 £ .00
Other sources (not included above)	E85 £ 224352.00
Total of boxes E50 to E85	E90 £ 224352.00

Enter details of expenditure as shown in the charity's/CASC's accounts for the period covered by these supplementary pages

Type of expenditure	Amount
Trading costs in relation to exempt charitable activities (in box E50)	E95 £ .00
UK land and buildings costs in relation to exempt charitable activities (in box E60)	E100 £ .00
All general administration/governance costs	E105 £ .00
All grants and donations made within the UK	E110 £ .00
All grants and donations made outside the UK	E115 £ .00
Other expenditure not included above, or not used in calculating figures entered on the form CT600	E120 £ 290856.00
Total of boxes E95 to E120	E125 £ 290856.00

UK Oncology Nursing Society

Information required

Charity/CASC assets

	Disposals in period (total consideration received)	Held at the end of the period (use accounts figures)
Tangible fixed assets	E130 £	E135 £
UK investments (excluding controlled companies)	E140 £	E145 £
Shares in, and loans to, controlled companies	E150 £	E155 £
Overseas investments	E160 £	E165 £
Loans and non-trade debtors		E170 £
Other current assets		E175 £ 204903
Qualifying investments and loans *Applies to charities only. See CT600 Guide*		E180
Value of any non-qualifying investments and loans *Applies to charities only. See CT600 Guide*		E185 £
Number of subsidiary or associated companies the charity controls at the end of the period. Exclude companies that were dormant throughout the period		E190

UK Oncology Nursing Society

THE UK ONCOLOGY NURSING SOCIETY

England & Wales - Charity number 1136972

Accounts

The UK Oncology Nursing Society

Trustees' Report

Year Ended 31 March 2023

The trustees have pleasure in presenting their report and the unaudited financial statements of the charitable company for the year ended 31 March 2023.

Status

The charitable company is limited by guarantee, having no share capital. Under the provisions of Section 60 of the Companies Act 2006, the company is entitled to omit the word "Limited" from its name. The governing document of the charitable company is its Memorandum and Articles of Association.

The charitable company is also known as UKONS.

Objects and Activities of the Charity

The objects of the charitable company are, for the public benefit:

1. To advance health and to relieve those in need by reason of ill-health, including without limitation people affected by cancer; and

2. To advance the education of the public in the subjects of health, medical and nursing care, including without limitation the causes, effects and treatments of cancer.

Aims of the charity

- To promote excellence in the nursing care and management of all those directly and indirectly affected by cancer.
- To encourage and facilitate the personal and professional development of nurses engaged in cancer care throughout the UK and overseas through education, research and policy.
- To share information about research, learning and development opportunities with UKONS members.
- To contribute to the development of cancer policy, clinical practice and service delivery nationally and internationally.
- To foster alliances and develop UK and international networking opportunities.

Activities and achievements aligned to the charity's aims for the year 2022/23

- Continuation of the Members Interest Groups: Living with and Beyond Cancer; Acute Oncology Services; Systemic Anti-cancer Treatments; Radiotherapy; Haemato-oncology; Lead Cancer Nurses; Research and our newest Members Interest Group- 'Young and Early Career Cancer Nurses'
- Continuation of our provision of the UKONS website (www.ukons.org), catering to the needs of members and the members interest groups.
- Continued publication of fortnightly editions of UKONS 'Breaking News' bulletin, supporting practice development and career progression, which is sent to all members via e-mail. This includes cancer nurse job advertisements for UKONS members. These advertisements are provided free of charge to advertisers.
- During 2022/23 Breaking News continued to be delivered jointly between UKONS and Macmillan Cancer Care due to an ongoing and developing partnership. This was underpinned by an MOU agreed and signed by both parties, renewed in 2022.
- In November 2022 we held our first face to face annual conference since the COVID pandemic in 2020. This was held in Belfast UK and was very successful with a record number of delegates registering and attending with the highest number of poster submissions ever received in UKONS history. The event focussed on a theme of 'Cancer Care in the Digital Age'. This provided the opportunity for cancer nurses to discuss, and present posters on supportive cancer

care, communicating with patients in modern cancer care; and the future of acute cancer care. This year, as with the previous eight, the conference abstract booklet was made available to delegates. This
year it was again presented in electronic format and it is likely that it will continue to be produced in in this form annually.

- UKONS continued to work with the Global Power of Oncology Nursing to support and facilitate their conference during 2023.
- Work continued to produce a web-based version of the UKONS Systemic Anti-cancer Therapy (SACT) Competency Passport together with our partner is Tefogo Ltd. We aim to deliver this enhancement free to UKONS members during late 2023.
- During 2022/23 UKONS continued to chair the UK SACT Board (formally UK Chemotherapy Board) delivering guidelines across all four nations for the delivery of systemic anti-cancer therapies
- UKONS continued to be a central organisation in developing and delivering the ACCEND (Aspirant Cancer Career and Education Development) programme. This career framework provides guidance and structure or all health care professionals wishing to develop a career in cancer care.
- Continued to approve translations of the UKONS Acute Oncology Triage Tool as well as working to formalise and deliver electronic versions of the tool.
- UKONS worked in partnership with the UK Acute Oncology Society and Macmillan to standardise AO education, training and assessment and advanced work on multi-professional AO competency passports, these will be piloted in mid-2023.
- Work commenced and continued on a book on the impact of the COVID pandemic in cancer care across Europe in partnership with Springer Press.
- Organised and presented education, training sessions and symposia at virtual and face-to-face events for both UKONS and other organisations throughout the year, including the UK Oncology Forum and the Oncology Professional Care Conference.
- Further developed the activities of UKONS Champions, with Young and Early Career Cancer Nurse input into a wide range of programmes and events. The champions worked to establish a sub-groups for both UKONS board alumni and Cancer Information Nurses.
- In 2023 UKONS hosted the European Cancer Nursing Day in Edinburgh, Scotland in partnership with the European Oncology Nursing Society (EONS).
- Continued to work with a wide range of industry partners and develop further relationships, extending our numbers of partners to more than 20.
- Collaborated with: NHS England, UK Oncology Forum; British Journal of Nursing; Cancer Nursing Practice, The European Oncology Nursing Society (EONS); International Society of Nurses in Cancer Care (ISNCC); and Oncology Professional Care
- Representation at the UK Chemotherapy Board; various NHS Working Groups (including those on SACT Capacity and Workforce); Macmillan Cancer Support/HEE.

Organisational Structure

The Board has four executive officers: President, Past President, Secretary and Treasurer. It has an additional ten full Board members who are all Trustees. New Trustees receive induction into their role on the Board.

Assessment of going concern

The charity's income is reliant on sponsorship from UKONS Partners, Income has been maintained despite ongoing uncertainty related to the UK and global economy and the COVID-19 pandemic. The board maintain a cautious approach and these factors have been considered in budgeting resources for the next financial year.

The UK Oncology Nursing Society

Trustees' Report

Year Ended 31 March 2023

Directors and Trustees

The directors and trustees who served the company during the year and up to the date of this report were as follows:

Mark Foulkes (President)
Karen Campbell (President Elect)
Lyndel Moore (Treasurer)
Deborah Wightman (Secretary)
Verna Lavender (Past President)
Nalayini Kumaralingam
Kay Bell
Lisa Barrott
Mark Foulkes
Mary Tanay
Libby Potter
Joanne Bird
Tracy Wilson
Rosemary Roberts
Naomi Clatworthy
Ruth Hammond
Constance Rowell

Reserves

The Trustees plan to retain a modest level of reserves as a contingency fund against future demands on the charity's resources whilst using available funds to further our charitable aims.

Small Company Provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Signed on behalf of the directors



Mark Foulkes
Director

Approved on ……31st August 2023

The UK Oncology Nursing Society

Unaudited Financial Statements

Year Ended 31 March 2023

Company Registration Number 06996552
Charity Registration Number 1136972

The UK Oncology Nursing Society

Financial Statements

Year Ended 31 March 2023

Contents **Page**

Trustees' Report	1
Independent Examiner’s Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7

The UK Oncology Nursing Society

Trustees' Report

Year Ended 31 March 2023

The trustees have pleasure in presenting their report and the unaudited financial statements of the charitable company for the year ended 31 March 2023.

Status

The charitable company is limited by guarantee, having no share capital. Under the provisions of Section 60 of the Companies Act 2006, the company is entitled to omit the word "Limited" from its name. The governing document of the charitable company is its Memorandum and Articles of Association.

The charitable company is also known as UKONS.

Objects and Activities of the Charity

The objects of the charitable company are, for the public benefit:

1. To advance health and to relieve those in need by reason of ill-health, including without limitation people affected by cancer; and

2. To advance the education of the public in the subjects of health, medical and nursing care, including without limitation the causes, effects and treatments of cancer.

Aims of the charity

- To promote excellence in the nursing care and management of all those directly and indirectly affected by cancer.
- To encourage and facilitate the personal and professional development of nurses engaged in cancer care throughout the UK and overseas through education, research and policy.
- To share information about research, learning and development opportunities with UKONS members.
- To contribute to the development of cancer policy, clinical practice and service delivery nationally and internationally.
- To foster alliances and develop UK and international networking opportunities.

Activities and achievements aligned to the charity's aims for the year 2022/23

- Continuation of the Members Interest Groups: Living with and Beyond Cancer; Acute Oncology Services; Systemic Anti-cancer Treatments; Radiotherapy; Haemato-oncology; Lead Cancer Nurses; Research
- A further Members Interest Group- 'Young and Early Career Cancer Nurses' was added in 2021 and continues to develop.
- Continuation of our provision of the UKONS website (www.ukons.org), catering to the needs of members and the members interest groups
- Continued publication of fortnightly editions of UKONS 'Breaking News' bulletin, supporting practice development and career progression, which is sent to all members via e-mail. This includes cancer nurse job advertisements for UKONS members. These advertisements are provided free of charge to advertisers.
- During 2022/23 Breaking News continued to be delivered jointly between UKONS and Macmillan Cancer Care due to an ongoing and developing partnership. This was underpinned by an MOU agreed and signed by both parties, renewed in 2022.
- In November 2022 we held our first face to face annual conference since the COVID pandemic in 2020. This was held in Belfast UK and was very successful with a record number of delegates registering and attending with the highest number of poster submissions ever received in UKONS history. The event focussed on a theme of 'Cancer Care in the Digital Age'.

This provided the opportunity for cancer nurses to discuss, and present posters on supportive cancer care, communicating with patients in modern cancer care; and the future of acute cancer care. This year, as with the previous eight, the conference abstract booklet was made available to delegates. This year it was again presented in electronic format and it is likely that it will continue to be produced in in this form annually.

- UKONS continued to work with the Global Power of Oncology Nursing to support and facilitate their conference during 2023.
- Work continued to produce a web-based version of the UKONS Systemic Anti-cancer Therapy (SACT) Competency Passport together with our partner is Tefogo Ltd. We aim to deliver this enhancement free to UKONS members during late 2023.
- During 2022/23 UKONS continued to chair the UK SACT Board (formally UK Chemotherapy Board) delivering guidelines across all four nations for the delivery of systemic anti-cancer therapies
- UKONS continued to be a central organisation in developing and delivering the ACCEND (Aspirant Cancer Career and Education Development) programme. This career framework provides guidance and structure or all health care professionals wishing to develop a career in cancer care.
- Continued to approve translations of the UKONS Acute Oncology Triage Tool as well as working to formalise and deliver electronic versions of the tool.
- UKONS worked in partnership with the UK Acute Oncology Society and Macmillan to standardise AO education, training and assessment and advanced work on multi-professional AO competency passports, these will be piloted in mid-2023.
- Work commenced and continued on a book on the impact of the COVID pandemic in cancer care across Europe in partnership with Springer Press.
- Organised and presented education, training sessions and symposia at virtual and face-to-face events for both UKONS and other organisations throughout the year, including the UK Oncology Forum and the Oncology Professional Care Conference.
- Further developed the activities of UKONS Champions, with Young and Early Career Cancer Nurse input into a wide range of programmes and events. The champions worked to establish a sub-groups for both UKONS board alumni and Cancer Information Nurses.
- In 2023 UKONS hosted the European Cancer Nursing Day in Edinburgh, Scotland in partnership with the European Oncology Nursing Society (EONS).
- Continued to work with a wide range of industry partners and develop further relationships, extending our numbers of partners to more than 20.
- Collaborated with: NHS England, UK Oncology Forum; British Journal of Nursing; Cancer Nursing Practice, The European Oncology Nursing Society (EONS); International Society of Nurses in Cancer Care (ISNCC); and Oncology Professional Care
- Representation at the UK Chemotherapy Board; various NHS Working Groups (including those on SACT Capacity and Workforce); Macmillan Cancer Support/HEE.

Organisational Structure

The Board has four executive officers: President, Past President, Secretary and Treasurer. It has an additional ten full Board members who are all Trustees. New Trustees receive induction into their role on the Board.

Assessment of going concern

The charity's income is reliant on sponsorship from UKONS Partners, Income has been maintained despite ongoing uncertainty related to the UK and global economy and the COVID-19 pandemic. The board maintain a cautious approach and these factors have been considered in budgeting resources for the next financial year.

Directors and Trustees

The directors and trustees who served the company during the year and up to the date of this report were as follows:

Mark Foulkes (President)
Karen Campbell (President Elect)
Lyndel Moore (Treasurer) (Appointed 11 November 2022)
Deborah Wightman (Secretary)
Verna Lavender (Past President)
Nalayini Kumaralingam
Kay Bell
Lisa Barrott
Mark Foulkes
Mary Tanay
Sam Wigfall
Libby Potter
Jo Bird
Tracy Wilson
Rosemary Roberts
Naomi Clatworthy
Ruth Hammond
Constance Rowell

Reserves

The Trustees plan to retain a modest level of reserves as a contingency fund against future demands on the charity's resources.

Small Company Provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Signed on behalf of the directors

Mark Foulkes
Director

Approved on 17/11/2023

The UK Oncology Nursing Society

Independent Examiner's Report to the Trustees

Year Ended 31 March 2023

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2023.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Martin Hobbs BSc ACA
Francis Clark LLP
Chartered Accountants
Sigma House
Oak View Close
Edginswell Park
Torquay
TQ2 7FF

Date: 28 November 2023

The UK Oncology Nursing Society

Statement of Financial Activities (incorporating an Income and Expenditure Account)

Year Ended 31 March 2023

	Unrestricted Funds £	Restricted Funds £	Total 2023 £	Total 2022 £
Income from:				
Partnership income	**80,833**	**-**	**80,833**	109,000
Corporate membership	**-**	**-**	**-**	2,000
Board activity	**14,691**	**-**	**14,691**	200
Donations	**4,100**	**-**	**4,100**	10
Other income	**1,025**	-	**1,025**	-
Total	**100,649**	**-**	**100,649**	111,210
Expenditure on:				
EONS membership fee	**893**	**-**	**893**	756
ISNCC membership fee	**244**	**-**	**244**	-
EBN Health book	**-**	**28**	**28**	6,122
Palliative care booklet	**2,450**	**-**	**2,450**	-
Board meetings – Travel and subsistence	**8,970**	**-**	**8,970**	1,270
Entertaining/other meetings	**11,055**	**-**	**11,055**	1,862
MIGs	**7,629**	**-**	**7,629**	3,735
Administrative support	**15,760**	**-**	**15,760**	17,053
Secretarial services	**330**	**-**	**330**	1,388
Legal and professional	**2,601**	**-**	**2,601**	250
Annual conference	**22,500**	**-**	**22,500**	9,710
Other conferences	**11,084**	**-**	**11,084**	2,475
Stationery and admin	**17**	**-**	**17**	513
Website and social media	**7,013**	**-**	**7,013**	14,988
Accounting fees	**5,475**	**-**	**5,475**	4,225
Insurance	**848**	**-**	**848**	933
SACT passport project	**20,000**	**-**	**20,000**	-
Champions' workshop	**31**	**-**	**31**	-
Irrecoverable VAT	**6,931**	**-**	**6,931**	1,420
Grants	**15,000**	**-**	**15,000**	20,000
Purchases	**10,230**	**-**	**10,230**	4,010
Total	**149,061**	**28**	**149,089**	90,710
Net income/(expenditure)	(48,412)	(28)	(48,440)	20,500
Total funds brought forward	232,072	5,175	237,247	216,747
Total funds carried forward	**183,660**	**5,147**	**188,807**	237,247

All of the incoming resources of the charity for the comparative year are unrestricted. All of the above results are derived from continuing activities. All gains and losses recognised in the year are included above. The result for the year for Companies Act purposes is equivalent to the net income / (expenditure).

The UK Oncology Nursing Society

Balance Sheet

31 March 2023

	Notes	2023 £	2022 £
Current assets			
Debtors	**4**	**22,120**	-
Cash at bank and in hand		**252,811**	283,078
		274,931	283,078
Liabilities			
Creditors falling due within one year	**5**	**(86,124**)	(45,831)
Total assets less current liabilities		**188,807**	237,247
Unrestricted funds	**6**	183,660	232,072
Restricted funds	**6**	5,147	5,175
Total funds		**188,807**	237,247

The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the financial statements for the year by virtue of section 477, and that no member or members have requested an audit pursuant to section 476 of the Act.

The directors acknowledge their responsibilities for:

(i) ensuring that the company keeps adequate accounting records which comply with section 386 of the Act, and

(ii) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the financial year in accordance with the requirements of sections 394 and 395, and which otherwise comply with the requirements of the Act relating to financial statements, so far as is applicable to the company.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act.

These financial statements were approved and signed by the trustees and authorised for issue on 17 November 2023 , and are signed on their behalf by:

……..
Mark Foulkes
Director

Company Registration Number: 06996552

1 Accounting Policies

Basis of accounting

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation of financial statements and assessment of going concern

The financial statements have been prepared under the historical cost convention and in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The UK Oncology Nursing Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The functional and presentational currency of these financial statements is sterling.

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

b) Income

Income is recognised when the charity has entitlement to funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Capital grants receivable are credited to the SOFA as they become receivable and are treated as restricted funds. The depreciation on the assets to which the grants relate is charged against these funds.

c) Fund accounting

Unrestricted funds are funds available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds received which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes.

d) Expenditure

Expenditure is recognised once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure includes irrecoverable VAT.

e) Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. The company holds the following financial instruments, all of which are considered to be basic:

- Short term debtors and creditors
- Cash and bank balances

2 Related Party Transactions

During the year travel expenses of £12,164 were reimbursed to 15 trustees (2022: £1,606 to 10 trustees).

3 Company Limited by Guarantee

The company is limited by guarantee and has no share capital. In the event of a winding-up, the liability of the members is limited to £1 each. The Charity is incorporated in England and Wales. The address of its registered office is: Legalinx, 14-18 City Road, Cardiff, Wales, CF24 3DL.

4 Debtors

	2023 £	2022 £
Trade debtors	**20,005**	**-**
Prepayments and accrued income	**2,115**	**-**
	22,120	**-**

5 Creditors: amounts falling due within one year

	2023 £	2022 £
Accruals and deferred income	**62,059**	21,955
VAT payable	**3,709**	3,020
Other creditors	**20,356**	20,856
	86,124	45,831

6 Analysis of movement on funds

	Balance at 1 April 2022 £	Incoming resources £	Resources expended £	Balance at 31 March 2023 £
Total unrestricted funds	232,072	100,649	(149,061)	**183,660**
Restricted funds:				
AOS education grant	2,230	**-**	**-**	**2,230**
EBN book grant	2,945	**-**	(28)	**2,917**
	237,247	100,649	(149,089)	**188,807**

The AOS education grant represents funds raised for the development of a digital friendly format for UKONS guidance for assessment of patients.

The EBN book grant represents funds raised for the writing and publication of a reference book entitled “Fundamentals of Cancer Care”.

The restricted funds are all held as cash at bank and in hand.

The UK Oncology Nursing Society

Trustees' Report

Year Ended 31 March 2023

The trustees have pleasure in presenting their report and the unaudited financial statements of the charitable company for the year ended 31 March 2023.

Status

The charitable company is limited by guarantee, having no share capital. Under the provisions of Section 60 of the Companies Act 2006, the company is entitled to omit the word "Limited" from its name. The governing document of the charitable company is its Memorandum and Articles of Association.

The charitable company is also known as UKONS.

Objects and Activities of the Charity

The objects of the charitable company are, for the public benefit:

1. To advance health and to relieve those in need by reason of ill-health, including without limitation people affected by cancer; and

2. To advance the education of the public in the subjects of health, medical and nursing care, including without limitation the causes, effects and treatments of cancer.

Aims of the charity

- To promote excellence in the nursing care and management of all those directly and indirectly affected by cancer.
- To encourage and facilitate the personal and professional development of nurses engaged in cancer care throughout the UK and overseas through education, research and policy.
- To share information about research, learning and development opportunities with UKONS members.
- To contribute to the development of cancer policy, clinical practice and service delivery nationally and internationally.
- To foster alliances and develop UK and international networking opportunities.

Activities and achievements aligned to the charity's aims for the year 2022/23

- Continuation of the Members Interest Groups: Living with and Beyond Cancer; Acute Oncology Services; Systemic Anti-cancer Treatments; Radiotherapy; Haemato-oncology; Lead Cancer Nurses; Research and our newest Members Interest Group- 'Young and Early Career Cancer Nurses'
- Continuation of our provision of the UKONS website (www.ukons.org), catering to the needs of members and the members interest groups.
- Continued publication of fortnightly editions of UKONS 'Breaking News' bulletin, supporting practice development and career progression, which is sent to all members via e-mail. This includes cancer nurse job advertisements for UKONS members. These advertisements are provided free of charge to advertisers.
- During 2022/23 Breaking News continued to be delivered jointly between UKONS and Macmillan Cancer Care due to an ongoing and developing partnership. This was underpinned by an MOU agreed and signed by both parties, renewed in 2022.
- In November 2022 we held our first face to face annual conference since the COVID pandemic in 2020. This was held in Belfast UK and was very successful with a record number of delegates registering and attending with the highest number of poster submissions ever received in UKONS history. The event focussed on a theme of 'Cancer Care in the Digital Age'. This provided the opportunity for cancer nurses to discuss, and present posters on supportive cancer

care, communicating with patients in modern cancer care; and the future of acute cancer care. This year, as with the previous eight, the conference abstract booklet was made available to delegates. This
year it was again presented in electronic format and it is likely that it will continue to be produced in in this form annually.

- UKONS continued to work with the Global Power of Oncology Nursing to support and facilitate their conference during 2023.
- Work continued to produce a web-based version of the UKONS Systemic Anti-cancer Therapy (SACT) Competency Passport together with our partner is Tefogo Ltd. We aim to deliver this enhancement free to UKONS members during late 2023.
- During 2022/23 UKONS continued to chair the UK SACT Board (formally UK Chemotherapy Board) delivering guidelines across all four nations for the delivery of systemic anti-cancer therapies
- UKONS continued to be a central organisation in developing and delivering the ACCEND (Aspirant Cancer Career and Education Development) programme. This career framework provides guidance and structure or all health care professionals wishing to develop a career in cancer care.
- Continued to approve translations of the UKONS Acute Oncology Triage Tool as well as working to formalise and deliver electronic versions of the tool.
- UKONS worked in partnership with the UK Acute Oncology Society and Macmillan to standardise AO education, training and assessment and advanced work on multi-professional AO competency passports, these will be piloted in mid-2023.
- Work commenced and continued on a book on the impact of the COVID pandemic in cancer care across Europe in partnership with Springer Press.
- Organised and presented education, training sessions and symposia at virtual and face-to-face events for both UKONS and other organisations throughout the year, including the UK Oncology Forum and the Oncology Professional Care Conference.
- Further developed the activities of UKONS Champions, with Young and Early Career Cancer Nurse input into a wide range of programmes and events. The champions worked to establish a sub-groups for both UKONS board alumni and Cancer Information Nurses.
- In 2023 UKONS hosted the European Cancer Nursing Day in Edinburgh, Scotland in partnership with the European Oncology Nursing Society (EONS).
- Continued to work with a wide range of industry partners and develop further relationships, extending our numbers of partners to more than 20.
- Collaborated with: NHS England, UK Oncology Forum; British Journal of Nursing; Cancer Nursing Practice, The European Oncology Nursing Society (EONS); International Society of Nurses in Cancer Care (ISNCC); and Oncology Professional Care
- Representation at the UK Chemotherapy Board; various NHS Working Groups (including those on SACT Capacity and Workforce); Macmillan Cancer Support/HEE.

Organisational Structure

The Board has four executive officers: President, Past President, Secretary and Treasurer. It has an additional ten full Board members who are all Trustees. New Trustees receive induction into their role on the Board.

Assessment of going concern

The charity's income is reliant on sponsorship from UKONS Partners, Income has been maintained despite ongoing uncertainty related to the UK and global economy and the COVID-19 pandemic. The board maintain a cautious approach and these factors have been considered in budgeting resources for the next financial year.

The UK Oncology Nursing Society

Trustees' Report

Year Ended 31 March 2023

Directors and Trustees

The directors and trustees who served the company during the year and up to the date of this report were as follows:

Mark Foulkes (President)
Karen Campbell (President Elect)
Lyndel Moore (Treasurer)
Deborah Wightman (Secretary)
Verna Lavender (Past President)
Nalayini Kumaralingam
Kay Bell
Lisa Barrott
Mark Foulkes
Mary Tanay
Libby Potter
Joanne Bird
Tracy Wilson
Rosemary Roberts
Naomi Clatworthy
Ruth Hammond
Constance Rowell

Reserves

The Trustees plan to retain a modest level of reserves as a contingency fund against future demands on the charity's resources whilst using available funds to further our charitable aims.

Small Company Provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Signed on behalf of the directors



Mark Foulkes
Director

Approved on ……31st August 2023

THE UK ONCOLOGY NURSING SOCIETY

England & Wales - Charity number 1136972

Accounts

UK Oncology Nursing Society

Registered in England and Wales - Company number: 06996552

Registered Office:

UK Oncology Nursing Society
First Floor
10 Queen Street Place
LONDON
EC4R 1BE

FRANCIS CLARK LLP
Sigma House
Oak View Close
Edginswell Park
Torquay
TQ2 7FF

Dear Sirs

Financial Statements of UK Oncology Nursing Society for the year ended 31 March 2022

The following representations are given to you in connection with your review of the charitable company's financial statements for the year ended 31 March 2022.

We confirm that the following representations are made on the basis of enquiries of management and staff of the charitable company with relevant knowledge and experience (and, where appropriate, of inspection of supporting documentation) sufficient to satisfy ourselves that we can properly make each of the following representations to you.

1. **Responsibility for the Financial Statements**

   We acknowledge as trustees our responsibility for the financial statements which you have prepared on our behalf for the charitable company and in particular confirm that we have selected suitable accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent.

   We also acknowledge our responsibilities for:

   a. Keeping adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and which enable us to ensure that the financial statements comply with the Companies Act 2006, UK Generally Accepted Accounting Practice (UK GAAP) and Statement of Recommended Practice 'Accounting and Reporting by Charities' (Charities SORP (FRS 102)).

   b. Safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

2. **Assets**

   We confirm that all assets have been included in the balance sheet and exist.

   We confirm that the charitable company has satisfactory title to all assets, and there are no liens or encumbrances on the assets except for those disclosed in the financial statements

   We confirm that the cost (or value) of all the assets in the balance sheet is fairly stated.

   We confirm that depreciation has been provided on all fixed assets with a limited economic life in accordance with the stated accounting policy. In our opinion, the rates of depreciation are reasonable.

3. **Liabilities**

   All liabilities of the charitable company of which we have knowledge are included in the appropriate classifications and we have no knowledge of any pending litigation or other claims against the charitable

company, or any contingent liabilities or capital commitments. No liabilities are 'secured' by reason of suppliers restricting the transfer of title to goods supplied.

The charitable company has no charitable commitments at the balance sheet date, other than as included or disclosed in the financial statements.

4. **Income and expenditure**

We confirm that all income and expenses have been fully recorded and correctly classified in the correct fund

We confirm that all grants, donations and other income, including those subject to special terms or conditions or received for restricted purpose, have been notified to you. There have been no breaches of terms or conditions during the period regarding the application of such income.

5. **Transactions with trustees**

The charitable company has not at any time during the year had any transactions with trustees or connected or related parties other than as disclosed in the financial statements.

The charitable company has had at no time during the year any arrangement, transaction or agreement to provide credit facilities (including loans, quasi-loans or credit transactions) for trustees, nor to guarantee or provide security for such matters, except as disclosed in note to the financial statements.

6. **Related parties**

We confirm that we are aware that a related party of the charitable company is a person or organisation which either (directly or indirectly) controls, has joint control of, or significantly influences the charitable company or vice versa and as a result will include: trustees, other key management, close family and other business interests of the previous. We confirm that we have disclosed to you the identity of all related parties and all the related party relationships and transactions of which we are aware.

7. **Completeness of Information**

All the accounting records have been made available to you for the purpose of preparing the financial statements and all the transactions undertaken by the charitable company have been properly reflected and recorded in the accounting records. All other records and related information, including minutes of all management and trustees' meetings (held during the year and up to the date of this letter) have been made available to you.

8. **Going Concern**

We confirm that, in our considered opinion, the charitable company is able to continue trading for the foreseeable future and for at least one year from the date of this letter. In arriving at this opinion, the trustees have considered the charitable company's current financial position, its current level of activity and all other relevant information.

9. **Post balance sheet events**

There has been no event since the balance sheet date which requires disclosure or which would materially affect the amounts in the accounts, other than those already disclosed or included in the financial statements.

10. **Laws and Regulations**

We confirm that there are no Laws or Regulations that are central to the charitable company's ability to conduct its business that may have an impact on amounts or disclosures in the financial statements.

11. **Reporting to regulator**

We confirm that we are not aware of any matters of material significance that should be reported to the Charity Commission.

Yours faithfully

…… [Signed on behalf of the Board]

18th December 2022 …… [Date]

The UK Oncology Nursing Society

Unaudited Financial Statements

Year Ended 31 March 2022

Company Registration Number 06996552
Charity Registration Number 1136972

The UK Oncology Nursing Society

Financial Statements

Year Ended 31 March 2022

Contents **Page**

Trustees' Report	1
Independent Examiner’s Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7

The trustees have pleasure in presenting their report and the unaudited financial statements of the charitable company for the year ended 31 March 2022.

Status

The charitable company is limited by guarantee, having no share capital. Under the provisions of Section 60 of the Companies Act 2006, the company is entitled to omit the word "Limited" from its name. The governing document of the charitable company is its Memorandum and Articles of Association.

The charitable company is also known as UKONS.

Objects and Activities of the Charity

The objects of the charitable company are, for the public benefit:

1. To advance health and to relieve those in need by reason of ill-health, including without limitation people affected by cancer; and

2. To advance the education of the public in the subjects of health, medical and nursing care, including without limitation the causes, effects and treatments of cancer.

Aims of the charity

- To promote excellence in the nursing care and management of all those directly and indirectly affected by cancer.
- To encourage and facilitate the personal and professional development of nurses engaged in cancer care throughout the UK and overseas through education, research and policy.
- To share information about research, learning and development opportunities with UKONS members.
- To contribute to the development of cancer policy, clinical practice and service delivery nationally and internationally.
- To foster alliances and develop UK and international networking opportunities.

Activities and achievements of the charity's aims for the year 2021/22

- Continuation of the Members Interest Groups: Living with and Beyond Cancer; Acute Oncology Services; Systemic Anti-cancer Treatments; Radiotherapy; Haemato-oncology; Lead Cancer Nurses; Research
- Addition of a further Members Interest Group- 'Young and Early Career Cancer Nurses'
- Continuation of our provision of the UKONS website (www.ukons.org), catering to the needs of members and the members interest groups
- Continued to develop our presence on social media with continuing interest in the UKONS Twitter Feed.
- Continued publication of fortnightly editions of UKONS 'Breaking News' bulletin, supporting practice development and career progression, which is sent to all members via e-mail. This includes cancer-nurse job advertisements for UKONS members. These advertisements are now provided free of charge to advertisers.
- During 2021/22 Breaking News was delivered jointly between UKONS and Macmillan Cancer Care due to an ongoing and developing partnership.
- In November 2021, we held the second annual conference delivered via a virtual conference platform. This choice was due to continued restrictions placed upon us by the COVID-19 pandemic with 325 delegates registering, focusing on a theme of 'Caring Connections'. This provided opportunity for cancer nurses to discuss educational standards in cancer nursing, personalised care, support and innovations in cancer nursing. The conference abstract booklet made available to delegates for an eighth consecutive year.

- This year the conference booklet was in electronic format it is likely that it will continue to be produced in electronic format going forward
- UKONS membership continued to grow across all four nations during 2021/22, reaching nearly 7200 members in November 2021
- Continued to work with the Global Power of Oncology Nursing to facilitate a conference session due to be presented during their 2022 conference
- Carried out a successful tender for a partner to create a web-based version of the UKONS Systemic Anti-cancer Therapy (SACT) Competency Passport. The chosen partner is Tefogo Ltd. During early 2022 work commenced to deliver the digital version of the passport free to UKONS members
- Supported Kidney Cancer UK in their bid for NICE to provide clear guidelines for the treatment of renal cancers. This bid was ultimately successful
- In early 2022 UKONS provided the chair for the UK Chemotherapy Board, delivering guidelines across all four nations for the delivery of systemic anti-cancer therapies
- Provided a grant to call for research examining the perception of risk in nurses delivering systemic anti-cancer therapies. This call was successful, the chosen research organisation being Edinburgh Napier University.
- UKONS was a pivotal organisation in developing and building the ACCEND (Aspirant Cancer Career and Education Development) programme. This will be a major piece of work providing a career framework and guidance for all health care professionals wishing to develop a career in cancer care across the UK. The programme will provide this structure from pre-registration through to clinical and strategic levels.
- Reviewed and shared research and survey participant invitations with UKONS members including a response to a call for input into the 10-year Cancer Plan
- The Research MIG delivered a Nursing research workshop in February 2022
- Approved Swedish and Italian translations of the UKONS Acute Oncology Triage Tool as well as some electronic versions of the triage tool
- UKONS reviewed and updated our corporate partnership arrangements amalgamating corporate and bronze level sponsorship to a single level (Bronze)
- A founder member of the National AO Standardised Education, Training and Assessment working group – aiming to develop UK standardised multi-professional AO competency passports
- The UKONS/Macmillan Position Statement on Staff who administer SACT drugs in the UK was formally endorsed and badged by the Royal College of Nursing
- Launched and successfully published the book 'Fundamentals of Cancer Care' in partnership with EBN Healthcare Publishers
- Organised and presented virtual/online education and training sessions and symposia at virtual masterclasses and conference events for both UKONS and other organisations throughout the year, including the UK Oncology Forum and the Oncology Professional care Conference.
- Developed a webpage and published education resources on Sexual Health and Wellbeing and Cancer
- Continued to deliver editorials and content for the British Journal of Nursing Oncology Supplement
- Further developed the activities of UKONS Champions, including a champions buddy system with Young and Early Career Cancer Nurse MIG and input into ACCEND programme and a wide range of oncology events and webinars
- Continued to work with a wide range of industry partners and develop further relationships.
- Collaborated with: UK Oncology Forum; British Journal of Nursing; Cancer Nursing Practice; Nursing Times; European Oncology Nursing Society (EONS); International Society of Nurses in Cancer Care (ISNCC); Oncology Nursing Society; Springer Press, Tefogo Ltd. Kidney Cancer UK, Royal College of Nursing: Cancer and Breast Care Forum, Trekstock, Evidence-based Networks Ltd (EBN Health) and Oncology Professional Care.

- Representation at the UK Chemotherapy Board; National Acute Oncology Steering Group; Macmillan Cancer Support/HEE PRosPER Steering Group; NHSE/I Oncology Workforce and Cancer Alliance Workforce Working Groups, ACCEND Programme, UK Acute Oncology Society, UK Association Supportive Cancer Care, Late Effects Community of Practice, Independent Sector Cancer Network. Mark Foulkes presented evidence to the UK Government Parliamentary Select Committee on Health with regard to Cancer and COVID-19 recovery.

Organisational Structure

The Board has four executive officers: President, Past President, Secretary and Treasurer. It has an additional ten full Board members who are all Trustees. New Trustees received induction into their role on the Board.

Assessment of going concern

The charity's income is reliant on sponsorship from UKONS Partners, and ongoing membership from corporate members. Despite some uncertainty post pandemic, income from our partners has been maintained and improved during this financial year. This income has been considered in budgeting and spending plans for the next financial year.

Directors and Trustees

The directors and trustees who served the company during the year and up to the date of this report were as follows:
Helen Roe
Verna Lavender
Nalayini Kumaralingam
Karen Campbell
Kay Bell
Lisa Barrott
Mark Foulkes
Una Cardin
Deborah Wightman
Mary Tanay
Sam Wigfall
Libby Potter
Jo Bird
Tracy Wilson
Rosemary Roberts (appointed 10 December 2021)
Naomi Clatworthy (appointed 10 December 2021)
Ruth Hammond (appointed 10 December 2021)
Constance Rowell (appointed 10 December 2021)
Helen Roe and Una Cardin completed their terms on the Board in November 2021

Reserves

The trustees planned to retain a modest level of reserves as a contingency fund against future demands on the charity's resources. We have been able to adjust our spending plans upwards in order to spend some of these reserves following exceeding our income target in 21/22.

Small Company Provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Signed on behalf of the directors

Mark Foulkes
Director

Approved on 18/12/2022

The UK Oncology Nursing Society

Independent Examiner's Report to the Trustees

Year Ended 31 March 2022

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2022.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Martin Hobbs BSc ACA
Francis Clark LLP
Chartered Accountants
Sigma House
Oak View Close
Edginswell Park
Torquay
TQ2 7FF

Date: …….

The UK Oncology Nursing Society

Statement of Financial Activities (incorporating an Income and Expenditure Account)

Year Ended 31 March 2022

	Unrestricted Funds £	Restricted Funds £	Total 2022 £	Total 2021 £
Income from:				
Partnership income	**109,000**	**-**	**109,000**	80,000
Corporate membership	**2,000**	**-**	**2,000**	3,400
EBN book grant	-	-	**-**	-
Other grant income	-	-	**-**	-
Advertising	-	-	-	5,500
Champions' workshop	-	-	-	7,500
Board activity	**200**	**-**	**200**	500
Donations	**10**	**-**	**10**	246
Other income	-	-	-	12,500
Total	**111,210**	**-**	**111,210**	109,646
Expenditure on:				
EONS membership fee	**756**	**-**	**756**	1,671
ISNCC membership fee	**-**	**-**	**-**	458
EBN Health book	**-**	**6,122**	**6,122**	12,600
Board meetings – Travel and subsistence	**1,270**	**-**	**1,270**	-
Entertaining/other meetings	**1,862**	**-**	**1,862**	121
MIGs	**3,735**	**-**	**3,735**	8,690
Administrative support	**17,053**	**-**	**17,053**	17,495
Secretarial services	**1,388**	**-**	**388**	12,500
Legal and professional	**250**	**-**	**250**	125
Annual conference	**9,710**	**-**	**9,710**	2,410
Other conferences	**2,475**	**-**	**2,475**	3,741
Stationery and admin	**513**	**-**	**513**	721
Website and social media	**14,988**	**-**	**14,988**	7,207
Accounting fees	**4,225**	**-**	**4,225**	3,032
Insurance	**933**	**-**	**933**	421
SACT passport project	**-**	**-**	**-**	(300)
Champions' workshop	**-**	**-**	**-**	9,695
Irrecoverable VAT	**1,420**	**-**	**1,420**	-
Grants	**20,000**	**-**	**20,000**	-
Purchases	**4,010**	**-**	**4,010**	-
Total	**84,588**	**6,122**	**90,710**	80,587
Net income/(expenditure)	**26,622**	**(6,122)**	**20,500**	29,059
Total funds brought forward	205,450	11,297	**216,747**	187,688
Total funds carried forward	**232,072**	**5,175**	**237,247**	216,747

All of the incoming resources of the charity for the comparative year are unrestricted. All of the above results are derived from continuing activities. All gains and losses recognised in the year are included above. The result for the year for Companies Act purposes is equivalent to the net incoming resources.

The UK Oncology Nursing Society

Balance Sheet

31 March 2022

	Notes	2022 £	2021 £
Current assets			
Cash at bank and in hand		**283,078**	226,685
Debtors	**4**	**-**	36,884
		283,078	263,569
Liabilities			
Creditors falling due within one year	**5**	**(45,831)**	(46,822)
Total assets less current liabilities		**237,247**	216,747
Unrestricted funds	**6**	**232,072**	205,450
Restricted funds	**6**	**5,175**	11,297
Total funds		**237,247**	216,747

The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the financial statements for the year by virtue of section 477, and that no member or members have requested an audit pursuant to section 476 of the Act.

The directors acknowledge their responsibilities for:

(i) ensuring that the company keeps adequate accounting records which comply with section 386 of the Act, and

(ii) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the financial year in accordance with the requirements of sections 394 and 395, and which otherwise comply with the requirements of the Act relating to financial statements, so far as is applicable to the company.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act.

These financial statements were approved and signed by the trustees and authorised for issue on ….18/12/222…….., and are signed on their behalf by:

……..
Mark Foulkes
Director

Company Registration Number: 06996552

1 Accounting Policies

Basis of accounting

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation of financial statements and assessment of going concern

The financial statements have been prepared under the historical cost convention and in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The UK Oncology Nursing Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The functional and presentational currency of these financial statements is sterling.

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

b) Income

Income is recognised when the charity has entitlement to funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Capital grants receivable are credited to the SOFA as they become receivable and are treated as restricted funds. The depreciation on the assets to which the grants relate is charged against these funds.

c) Fund accounting

Unrestricted funds are funds available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds received which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes.

d) Expenditure

Expenditure is recognised once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure includes irrecoverable VAT.

e) Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. The company holds the following financial instruments, all of which are considered to be basic:

- Short term debtors and creditors
- Cash and bank balances

2 Related Party Transactions

During the year travel expenses of £1,606 were reimbursed to 10 trustees (2021: £363 to 1 trustee).

3 Company Limited by Guarantee

The company is limited by guarantee and has no share capital. In the event of a winding-up, the liability of the members is limited to £1 each. The Charity is incorporated in England and Wales. The address of its registered office is: Legalinx, 14-18 City Road, Cardiff, Wales, CF24 3DL.

4 Debtors

	2022 £	2021 £
Trade debtors	**-**	35,950
Prepayments and accrued income	**-**	934
	-	36,884

5 Creditors: amounts falling due within one year

	2022 £	2021 £
Accruals and deferred income	**21,955**	38,763
VAT payable	**3,020**	8,059
Other creditors	**20,856**	-
	45,831	46,822

6 Analysis of movement on funds

	Balance at 1 April 2021 £	Incoming resources £	Resources expended £	Balance at 31 March 2022 £
Total unrestricted funds	205,450	111,210	(84,588)	**232,072**
Restricted funds:				
AOS education grant	2,230	-	-	**2,230**
EBN book grant	9,067	-	(6,122)	**2,945**
	216,747	111,210	(90,710)	**237,247**

The AOS education grant represents funds raised for the development of a digital friendly format for UKONS guidance for assessment of patients.

The EBN book grant represents funds raised for the writing and publication of a reference book entitled “Fundamentals of Cancer Care”.

The restricted funds are all held as cash at bank and in hand.

The UK Oncology Nursing Society

Unaudited Financial Statements

Year Ended 31 March 2022

Company Registration Number 06996552
Charity Registration Number 1136972

The UK Oncology Nursing Society

Financial Statements

Year Ended 31 March 2022

Contents **Page**

Trustees' Report	1
Independent Examiner’s Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7

The trustees have pleasure in presenting their report and the unaudited financial statements of the charitable company for the year ended 31 March 2022.

Status

The charitable company is limited by guarantee, having no share capital. Under the provisions of Section 60 of the Companies Act 2006, the company is entitled to omit the word "Limited" from its name. The governing document of the charitable company is its Memorandum and Articles of Association.

The charitable company is also known as UKONS.

Objects and Activities of the Charity

The objects of the charitable company are, for the public benefit:

1. To advance health and to relieve those in need by reason of ill-health, including without limitation people affected by cancer; and

2. To advance the education of the public in the subjects of health, medical and nursing care, including without limitation the causes, effects and treatments of cancer.

Aims of the charity

- To promote excellence in the nursing care and management of all those directly and indirectly affected by cancer.
- To encourage and facilitate the personal and professional development of nurses engaged in cancer care throughout the UK and overseas through education, research and policy.
- To share information about research, learning and development opportunities with UKONS members.
- To contribute to the development of cancer policy, clinical practice and service delivery nationally and internationally.
- To foster alliances and develop UK and international networking opportunities.

Activities and achievements of the charity's aims for the year 2021/22

- Continuation of the Members Interest Groups: Living with and Beyond Cancer; Acute Oncology Services; Systemic Anti-cancer Treatments; Radiotherapy; Haemato-oncology; Lead Cancer Nurses; Research
- Addition of a further Members Interest Group- 'Young and Early Career Cancer Nurses'
- Continuation of our provision of the UKONS website (www.ukons.org), catering to the needs of members and the members interest groups
- Continued to develop our presence on social media with continuing interest in the UKONS Twitter Feed.
- Continued publication of fortnightly editions of UKONS 'Breaking News' bulletin, supporting practice development and career progression, which is sent to all members via e-mail. This includes cancer-nurse job advertisements for UKONS members. These advertisements are now provided free of charge to advertisers.
- During 2021/22 Breaking News was delivered jointly between UKONS and Macmillan Cancer Care due to an ongoing and developing partnership.
- In November 2021, we held the second annual conference delivered via a virtual conference platform. This choice was due to continued restrictions placed upon us by the COVID-19 pandemic with 325 delegates registering, focusing on a theme of 'Caring Connections'. This provided opportunity for cancer nurses to discuss educational standards in cancer nursing, personalised care, support and innovations in cancer nursing. The conference abstract booklet made available to delegates for an eighth consecutive year.

- This year the conference booklet was in electronic format it is likely that it will continue to be produced in electronic format going forward
- UKONS membership continued to grow across all four nations during 2021/22, reaching nearly 7200 members in November 2021
- Continued to work with the Global Power of Oncology Nursing to facilitate a conference session due to be presented during their 2022 conference
- Carried out a successful tender for a partner to create a web-based version of the UKONS Systemic Anti-cancer Therapy (SACT) Competency Passport. The chosen partner is Tefogo Ltd. During early 2022 work commenced to deliver the digital version of the passport free to UKONS members
- Supported Kidney Cancer UK in their bid for NICE to provide clear guidelines for the treatment of renal cancers. This bid was ultimately successful
- In early 2022 UKONS provided the chair for the UK Chemotherapy Board, delivering guidelines across all four nations for the delivery of systemic anti-cancer therapies
- Provided a grant to call for research examining the perception of risk in nurses delivering systemic anti-cancer therapies. This call was successful, the chosen research organisation being Edinburgh Napier University.
- UKONS was a pivotal organisation in developing and building the ACCEND (Aspirant Cancer Career and Education Development) programme. This will be a major piece of work providing a career framework and guidance for all health care professionals wishing to develop a career in cancer care across the UK. The programme will provide this structure from pre-registration through to clinical and strategic levels.
- Reviewed and shared research and survey participant invitations with UKONS members including a response to a call for input into the 10-year Cancer Plan
- The Research MIG delivered a Nursing research workshop in February 2022
- Approved Swedish and Italian translations of the UKONS Acute Oncology Triage Tool as well as some electronic versions of the triage tool
- UKONS reviewed and updated our corporate partnership arrangements amalgamating corporate and bronze level sponsorship to a single level (Bronze)
- A founder member of the National AO Standardised Education, Training and Assessment working group – aiming to develop UK standardised multi-professional AO competency passports
- The UKONS/Macmillan Position Statement on Staff who administer SACT drugs in the UK was formally endorsed and badged by the Royal College of Nursing
- Launched and successfully published the book 'Fundamentals of Cancer Care' in partnership with EBN Healthcare Publishers
- Organised and presented virtual/online education and training sessions and symposia at virtual masterclasses and conference events for both UKONS and other organisations throughout the year, including the UK Oncology Forum and the Oncology Professional care Conference.
- Developed a webpage and published education resources on Sexual Health and Wellbeing and Cancer
- Continued to deliver editorials and content for the British Journal of Nursing Oncology Supplement
- Further developed the activities of UKONS Champions, including a champions buddy system with Young and Early Career Cancer Nurse MIG and input into ACCEND programme and a wide range of oncology events and webinars
- Continued to work with a wide range of industry partners and develop further relationships.
- Collaborated with: UK Oncology Forum; British Journal of Nursing; Cancer Nursing Practice; Nursing Times; European Oncology Nursing Society (EONS); International Society of Nurses in Cancer Care (ISNCC); Oncology Nursing Society; Springer Press, Tefogo Ltd. Kidney Cancer UK, Royal College of Nursing: Cancer and Breast Care Forum, Trekstock, Evidence-based Networks Ltd (EBN Health) and Oncology Professional Care.

- Representation at the UK Chemotherapy Board; National Acute Oncology Steering Group; Macmillan Cancer Support/HEE PRosPER Steering Group; NHSE/I Oncology Workforce and Cancer Alliance Workforce Working Groups, ACCEND Programme, UK Acute Oncology Society, UK Association Supportive Cancer Care, Late Effects Community of Practice, Independent Sector Cancer Network. Mark Foulkes presented evidence to the UK Government Parliamentary Select Committee on Health with regard to Cancer and COVID-19 recovery.

Organisational Structure

The Board has four executive officers: President, Past President, Secretary and Treasurer. It has an additional ten full Board members who are all Trustees. New Trustees received induction into their role on the Board.

Assessment of going concern

The charity's income is reliant on sponsorship from UKONS Partners, and ongoing membership from corporate members. Despite some uncertainty post pandemic, income from our partners has been maintained and improved during this financial year. This income has been considered in budgeting and spending plans for the next financial year.

Directors and Trustees

The directors and trustees who served the company during the year and up to the date of this report were as follows:
Helen Roe
Verna Lavender
Nalayini Kumaralingam
Karen Campbell
Kay Bell
Lisa Barrott
Mark Foulkes
Una Cardin
Deborah Wightman
Mary Tanay
Sam Wigfall
Libby Potter
Jo Bird
Tracy Wilson
Rosemary Roberts (appointed 10 December 2021)
Naomi Clatworthy (appointed 10 December 2021)
Ruth Hammond (appointed 10 December 2021)
Constance Rowell (appointed 10 December 2021)
Helen Roe and Una Cardin completed their terms on the Board in November 2021

Reserves

The trustees planned to retain a modest level of reserves as a contingency fund against future demands on the charity's resources. We have been able to adjust our spending plans upwards in order to spend some of these reserves following exceeding our income target in 21/22.

Small Company Provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Signed on behalf of the directors

Mark Foulkes
Director

Approved on 18/12/2022

The UK Oncology Nursing Society

Independent Examiner's Report to the Trustees

Year Ended 31 March 2022

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2022.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Martin Hobbs BSc ACA
Francis Clark LLP
Chartered Accountants
Sigma House
Oak View Close
Edginswell Park
Torquay
TQ2 7FF

Date: 19 December 2022

The UK Oncology Nursing Society

Statement of Financial Activities (incorporating an Income and Expenditure Account)

Year Ended 31 March 2022

	Unrestricted Funds £	Restricted Funds £	Total 2022 £	Total 2021 £
Income from:				
Partnership income	**109,000**	**-**	**109,000**	80,000
Corporate membership	**2,000**	**-**	**2,000**	3,400
EBN book grant	-	-	**-**	-
Other grant income	-	-	**-**	-
Advertising	-	-	-	5,500
Champions' workshop	-	-	-	7,500
Board activity	**200**	**-**	**200**	500
Donations	**10**	**-**	**10**	246
Other income	-	-	-	12,500
Total	**111,210**	**-**	**111,210**	109,646
Expenditure on:				
EONS membership fee	**756**	**-**	**756**	1,671
ISNCC membership fee	**-**	**-**	**-**	458
EBN Health book	**-**	**6,122**	**6,122**	12,600
Board meetings – Travel and subsistence	**1,270**	**-**	**1,270**	-
Entertaining/other meetings	**1,862**	**-**	**1,862**	121
MIGs	**3,735**	**-**	**3,735**	8,690
Administrative support	**17,053**	**-**	**17,053**	17,495
Secretarial services	**1,388**	**-**	**388**	12,500
Legal and professional	**250**	**-**	**250**	125
Annual conference	**9,710**	**-**	**9,710**	2,410
Other conferences	**2,475**	**-**	**2,475**	3,741
Stationery and admin	**513**	**-**	**513**	721
Website and social media	**14,988**	**-**	**14,988**	7,207
Accounting fees	**4,225**	**-**	**4,225**	3,032
Insurance	**933**	**-**	**933**	421
SACT passport project	**-**	**-**	**-**	(300)
Champions' workshop	**-**	**-**	**-**	9,695
Irrecoverable VAT	**1,420**	**-**	**1,420**	-
Grants	**20,000**	**-**	**20,000**	-
Purchases	**4,010**	**-**	**4,010**	-
Total	**84,588**	**6,122**	**90,710**	80,587
Net income/(expenditure)	**26,622**	**(6,122)**	**20,500**	29,059
Total funds brought forward	205,450	11,297	**216,747**	187,688
Total funds carried forward	**232,072**	**5,175**	**237,247**	216,747

All of the incoming resources of the charity for the comparative year are unrestricted. All of the above results are derived from continuing activities. All gains and losses recognised in the year are included above. The result for the year for Companies Act purposes is equivalent to the net incoming resources.

The UK Oncology Nursing Society

Balance Sheet

31 March 2022

	Notes	2022 £	2021 £
Current assets			
Cash at bank and in hand		**283,078**	226,685
Debtors	**4**	**-**	36,884
		283,078	263,569
Liabilities			
Creditors falling due within one year	**5**	**(45,831)**	(46,822)
Total assets less current liabilities		**237,247**	216,747
Unrestricted funds	**6**	**232,072**	205,450
Restricted funds	**6**	**5,175**	11,297
Total funds		**237,247**	216,747

The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the financial statements for the year by virtue of section 477, and that no member or members have requested an audit pursuant to section 476 of the Act.

The directors acknowledge their responsibilities for:

(i) ensuring that the company keeps adequate accounting records which comply with section 386 of the Act, and

(ii) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the financial year in accordance with the requirements of sections 394 and 395, and which otherwise comply with the requirements of the Act relating to financial statements, so far as is applicable to the company.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act.

These financial statements were approved and signed by the trustees and authorised for issue on ….18/12/222…….., and are signed on their behalf by:

……..
Mark Foulkes
Director

Company Registration Number: 06996552

1 Accounting Policies

Basis of accounting

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation of financial statements and assessment of going concern

The financial statements have been prepared under the historical cost convention and in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The UK Oncology Nursing Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The functional and presentational currency of these financial statements is sterling.

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

b) Income

Income is recognised when the charity has entitlement to funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Capital grants receivable are credited to the SOFA as they become receivable and are treated as restricted funds. The depreciation on the assets to which the grants relate is charged against these funds.

c) Fund accounting

Unrestricted funds are funds available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds received which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes.

d) Expenditure

Expenditure is recognised once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure includes irrecoverable VAT.

e) Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. The company holds the following financial instruments, all of which are considered to be basic:

- Short term debtors and creditors
- Cash and bank balances

2 Related Party Transactions

During the year travel expenses of £1,606 were reimbursed to 10 trustees (2021: £363 to 1 trustee).

3 Company Limited by Guarantee

The company is limited by guarantee and has no share capital. In the event of a winding-up, the liability of the members is limited to £1 each. The Charity is incorporated in England and Wales. The address of its registered office is: Legalinx, 14-18 City Road, Cardiff, Wales, CF24 3DL.

4 Debtors

	2022 £	2021 £
Trade debtors	**-**	35,950
Prepayments and accrued income	**-**	934
	-	36,884

5 Creditors: amounts falling due within one year

	2022 £	2021 £
Accruals and deferred income	**21,955**	38,763
VAT payable	**3,020**	8,059
Other creditors	**20,856**	-
	45,831	46,822

6 Analysis of movement on funds

	Balance at 1 April 2021 £	Incoming resources £	Resources expended £	Balance at 31 March 2022 £
Total unrestricted funds	205,450	111,210	(84,588)	**232,072**
Restricted funds:				
AOS education grant	2,230	-	-	**2,230**
EBN book grant	9,067	-	(6,122)	**2,945**
	216,747	111,210	(90,710)	**237,247**

The AOS education grant represents funds raised for the development of a digital friendly format for UKONS guidance for assessment of patients.

The EBN book grant represents funds raised for the writing and publication of a reference book entitled “Fundamentals of Cancer Care”.

The restricted funds are all held as cash at bank and in hand.